Peeters Protides of the Biological Fluids

Proceedings of the Twenty-Ninth Colloquium, 1981
1. Auflage 2014
ISBN: 978-1-4831-9032-7
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, Band Volume 29, 1010 Seiten, Web PDF

Reihe: Protides of the Biological Fluids

Protides of the Biological Fluids: An International Review Series Devoted to Proteins and Related Studies, Volume 29: Membrane Proteins, Receptor Ligand Interactions, Monoclonal Antibodies, New Methods focuses on membrane proteins, receptor-ligand interactions, and monoclonal proteins as a reagent. The selection first offers information on H-Y and sex determination and aspects of the difficulties to purify membrane proteins. Topics include solubilization by acylation, influence of supporting media on the aggregation of proteins, solubilization with detergents and organic solvents, and membrane proteins - giant detergent molecules. The text then examines the application of group-specific reagents for hydrophobic labeling and crosslinking of membrane proteins and comparison of secreted and membrane-bound human immunoglobulins M and D. The publication tackles sialoglycoproteins (glycophorins) in the plasma membranes of different cells and their receptor functions and the structures and antigenic properties of human erythrocyte membrane sialoglycoproteins. Discussions focus on the primary structure of human erythrocyte glycophorins, molecular structure of the MN bloodgroup substance, and genetic variants of glycophorin A. The book also takes a look at the glycoproteins of the human syncytiotrophoblastic plasma membrane and structure and function of a membrane glycoprotein encoded in the adenovirus genome. The selection is a valuable reference for readers interested in membrane proteins, receptor ligand interactions, and monoclonal antibodies.

Autoren/Hrsg.

Peeters, H.

Inhaltsverzeichnis

1;Front Cover;1
2;Protides of the Biological Fluids;4
3;Copyright Page;5
4;Table of Contents;6
5;PREFACE;26
6;ACKNOWLEDGEMENTS;28
7;The Tenth Arne Tiselius Memorial Lecture;30
7.1;CHAPTER 1. H-Y ANTIGEN AND SEX DETERMINATION;32
7.1.1;REFERENCES;38
8;SECTION A: Membrane Proteins;42
8.1;CHAPTER 2. SOME GENERAL ASPECTS OF THE DIFFICULTIES TO PURIFY MEMBRANE PROTEINS;44
8.1.1;ABSTRACT;44
8.1.2;KEYWORDS;44
8.1.3;INTRODUCTION;44
8.1.4;MEMBRANE PROTEINS - GIANT DETERGENT MOLECULES;45
8.1.5;SOLUBILIZATION WITH DETERGENTS;45
8.1.6;SOLUBILIZATION WITH ORGANIC SOLVENTS;48
8.1.7;SOLUBILIZATION BY ION-PAIR FORMATION;48
8.1.8;SOLUBILIZATION BY ACYLATION;49
8.1.9;THE INFLUENCE OF SUPPORTING MEDIA ON THE AGGREGATION OF PROTEINS;50
8.1.10;ACKNOWLEDGEMENTS;53
8.1.11;REFERENCES;53
8.2;CHAPTER 3. NEW APPLICATION OF GROUP-SPECIFIC REAGENTS FOR HYDROPHOBIC LABELING AND CROSSLINKING OF MEMBRANE PROTEINS;56
8.2.1;ABSTRACT;56
8.2.2;INTRODUCTION;56
8.2.3;NEW USE FOR "OLD" REAGENTS;57
8.2.4;WHAT' S NEXT?;58
8.2.5;CONCLUSIONS;59
8.2.6;ACKNOWLEDGMENTS;59
8.2.7;REFERENCES;60
8.3;CHAPTER 4. THE USE OF A ZWITTERIONIC DETERGENT AND A MONOCLONAL ANTIBODY IN PURIFICATION OF RAT LIVER 5'-NUCLEOTIDASE;62
8.3.1;ABSTRACT;62
8.3.2;KEYWORDS;62
8.3.3;INTRODUCTION;62
8.3.4;EXPERIMENTAL;62
8.3.5;RESULTS;63
8.3.6;DISCUSSION;64
8.3.7;ACKNOWLEDGEMENTS;64
8.3.8;REFERENCES;64
8.4;CHAPTER 5. HUMAN IgD, THE GENE AND THE PROTEIN;66
8.4.1;ABSTRACT;66
8.4.2;KEYWORDS;66
8.4.3;REFERENCES;69
8.5;CHAPTER 6. STRUCTURAL STUDIES OF HUMAN IgD;70
8.5.1;ABSTRACT;70
8.5.2;KEYWORDS;70
8.5.3;INTRODUCTION;70
8.5.4;RESULTS AND DISCUSSION;71
8.5.5;ACKNOWLEDGMENTS;73
8.5.6;REFERENCES;73
8.6;CHAPTER 7. COMPARISON OF SECRETED AND MEMBRANE-BOUND HUMAN IMMUNOGLOBULINS M AND D;74
8.6.1;ABSTRACT;74
8.6.2;KEYWORDS;74
8.6.3;INTRODUCTION;74
8.6.4;RESULTS AND DISCUSSION;75
8.6.5;ACKNOWLEDGEMENT;77
8.6.6;REFERENCES;77
8.7;CHAPTER 8. THE SIALOGLYCOPROTEINS (GLYCOPHORINS) IN THE PLASMA MEMBRANES OF DIFFERENT CELLS AND THEIR RECEPTOR FUNCTIONS;78
8.7.1;ABSTRACT;78
8.7.2;KEYWORDS;78
8.7.3;INTRODUCTION;78
8.7.4;THE PRIMARY STRUCTURE OF HUMAN ERYTHROCYTE GLYCOPHORINS;79
8.7.5;GLYCOPHORIN A IS EXPRESSED IN NUCLEATED PRECURSOR CELLS;81
8.7.6;THE MOLECULAR STRUCTURE OF THE MN BLOODGROUP SUBSTANCE;82
8.7.7;GENETIC VARIANTS OF GLYCOPHORIN A;84
8.7.8;REFERENCES;84
8.8;CHAPTER 9. STRUCTURES AND ANTIGENIC PROPERTIES OF HUMAN ERYTHROCYTE MEMBRANE SIALOGLYCOPROTEINS;86
8.8.1;ABSTRACT;86
8.8.2;KEY WORDS;86
8.8.3;INTRODUCTION;86
8.8.4;RESULTS AND DISCUSSION;88
8.8.5;ACKNOWLEDGEMENT;90
8.8.6;REFERENCES;91
8.9;CHAPTER 10. CYTOSKELETON-ASSOCIATED SURFACE GLYCOPROTEINS OF MURINE LYMPHOCYTES;92
8.9.1;ABSTRACT;92
8.9.2;KEYWORDS;92
8.9.3;INTRODUCTION;92
8.9.4;MATERIALS AND METHODS;92
8.9.5;RESULTS AND DISCUSSION;93
8.9.6;ACKNOWLEDGEMENTS;95
8.9.7;REFERENCES;95
8.10;CHAPTER 11. THE RELATIONSHIP BETWEEN DIFFERENTIATION OF FRIEND ERYTHROLEUKEMIA CELLS AND SYNTHESIS OF PLASMA MEMBRANE-BOUND GLYCOPROTEINS;96
8.10.1;ABSTRACT;96
8.10.2;KEYWORDS;96
8.10.3;INTRODUCTION;96
8.10.4;MATERIAL AND METHODS;96
8.10.5;RESULTS AND DISCUSSION;97
8.10.6;REFERENCES;99
8.11;CHAPTER 12. VARIATIONS IN THE STRUCTURE OF SURFACE GLYCOPROTEINS PRESENT IN DIFFERENT LYMPHOCYTE SUBPOPULATIONS;100
8.11.1;ABSTRACT;100
8.11.2;KEYWORDS;100
8.11.3;INTRODUCTION;100
8.11.4;MATERIALS AND METHODS;101
8.11.5;RESULTS AND DISCUSSION;101
8.11.6;ACKNOWLEDGEMENTS;103
8.11.7;REFERENCES;103
8.12;CHAPTER 13. ENHANCED NEURAMINIDASE-RESISTANT SIALIC ACID CONTENT IN THE SURFACE GLYCOPEPTIDES OF HUMAN LEUKAEMIC HAIRY CELLS;104
8.12.1;ABSTRACT;104
8.12.2;KEYWORDS;104
8.12.3;INTRODUCTION;104
8.12.4;METHODOLOGY;105
8.12.5;RESULTS;105
8.12.6;DISCUSSION;107
8.12.7;ACKNOWLEDGEMENT;107
8.12.8;REFERENCES;107
8.13;CHAPTER 14. RECONSTITUTION OF LIPOSOMES BEARING PLATELET MEMBRANE GLYCOPROTEINS. A FUNCTIONAL STUDY WITH VON WILLEBRAND FACTOR;108
8.13.1;ABSTRACT;108
8.13.2;KEYWORDS;108
8.13.3;INTRODUCTION;108
8.13.4;MATERIAL AND METHODS;109
8.13.5;RESULTS;109
8.13.6;DISCUSSION;111
8.13.7;REFERENCES;112
8.14;CHAPTER 15. HUMAN PLATELET MEMBRANE GLYCOPROTEINS llb AND Illa MAY FORM Ca2 +-DEPENDENT COMPLEXES;114
8.14.1;ABSTRACT;114
8.14.2;KEYWORDS;114
8.14.3;INTRODUCTION;114
8.14.4;MATERIALS AND METHODS;114
8.14.5;RESULTS AND DISCUSSION;115
8.14.6;CONCLUSIONS;117
8.14.7;REFERENCES;117
8.15;CHAPTER 16. GLYCOPROTEINS OF THE HUMAN SYNCYTIOTROPHOBLASTIC PLASMA MEMBRANE;118
8.15.1;ABSTRACT;118
8.15.2;KEY WORDS;118
8.15.3;INTRODUCTION;118
8.15.4;MATERIALS AND METHODS;119
8.15.5;RESULTS;119
8.15.6;DISCUSSION;120
8.15.7;ACKNOWLEDGEMENTS;121
8.15.8;REFERENCES;121
8.16;CHAPTER 17. CHARACTERIZATION OF a-TISSUE ANTIGEN (aTA), A MEMBRANE GLYCOPROTEIN OF CANCER CELLS;122
8.16.1;ABSTRACT;122
8.16.2;KEYWORDS;122
8.16.3;INTRODUCTION;122
8.16.4;MATERIALS AND METHODS;122
8.16.5;RESULTS;123
8.16.6;REFERENCES;125
8.17;CHAPTER 18. THE STRUCTURE AND FUNCTION OF A MEMBRANE GLYCOPROTEIN ENCODED IN THE ADENOVIRUS GENOME;126
8.17.1;ABSTRACT;126
8.17.2;KEY WORDS;126
8.17.3;INTRODUCTION;126
8.17.4;THE GENE FOR THE ADENOVIRUS GLYCOPROTEIN;126
8.17.5;REFERENCES;128
8.18;CHAPTER 19. PROTEIN MICELLES AND VIROSOMES FROM THE SURFACE GLYCOPROTEINS OF PARAINFLUENZA 3 VIRUS;130
8.18.1;ABSTRACT;130
8.18.2;KEYWORDS;130
8.18.3;INTRODUCTION;130
8.18.4;MATERIALS AND METHODS;130
8.18.5;RESULTS;131
8.18.6;REFERENCES;133
8.19;CHAPTER 20. HUMAN RED CELL MEMBRANE ACETYLCHOLINESTERASE, A MODEL ENZYME FOR THE STUDY OF PROTEIN-AMPHIPHILE INTERACTIONS;134
8.19.1;ABSTRACT;134
8.19.2;KEYWORDS;134
8.19.3;INTRODUCTION;134
8.19.4;ENZYME PURIFICATION;134
8.19.5;PROPERTIES OF THE PURIFIED ENZYME;136
8.19.6;ACKNOWLEDGEMENTS;137
8.19.7;REFERENCES;137
8.20;CHAPTER 21. SPECTRIN FREE VESICLES OBTAINED FROM HUMAN ERYTHROCYTES WITHOUT ATP-DEPLETION;138
8.20.1;ABSTRACT;138
8.20.2;KEYWORDS;138
8.20.3;INTRODUCTION;138
8.20.4;EXPERIMENTAL PROCEDURES;139
8.20.5;RESULTS;139
8.20.6;DISCUSSION;140
8.20.7;ACKNOWLEDGEMENT;141
8.20.8;REFERENCES;141
8.21;CHAPTER 22. ACYLATION OF INTEGRAL ERYTHROCYTE MEMBRANE PROTEINS RESULTING IN A SOLUBLE FORM OF BAND 3 PROTEIN;142
8.21.1;ABSTRACT;142
8.21.2;KEYWORDS;142
8.21.3;INTRODUCTION;142
8.21.4;MATERIALS AND METHODS;142
8.21.5;RESULTS;143
8.21.6;DISCUSSION;145
8.21.7;ACKNOWLEDGEMENTS;145
8.21.8;REFERENCES;145
8.22;CHAPTER 23. SELF-ASSOCIATION OF BAND 3 PROTEIN FROM ERYTHROCYTE MEMBRANES IN SOLUTIONS OF A NONIONIC DETERGENT, AMMONYX-LO;146
8.22.1;ABSTRACT;146
8.22.2;KEYWORDS;146
8.22.3;INTRODUCTION;146
8.22.4;MATERIALS AND METHODS;146
8.22.5;RESULTS;147
8.22.6;DISCUSSION;149
8.22.7;REFERENCES;149
8.23;CHAPTER 24. INTERACTIONS OF THE ISOLATED SPECTRIN POLYPEPTIDES (BANDS 1 AND 2) WITH PHOSPHOLIPID MONOLAYERS;150
8.23.1;ABSTRACT;150
8.23.2;KEYWORDS;150
8.23.3;INTRODUCTION;150
8.23.4;MATERIALS AND METHODS;151
8.23.5;RESULTS;151
8.23.6;DISCUSSION;151
8.23.7;ACKNOWLEDGEMENTS;153
8.23.8;REFERENCES;153
8.24;CHAPTER 25. RED CELL MEMBRANE CHANGES IN A HEINZ BODY ANAEMIA (KALE ANAEMIA);154
8.24.1;ABSTRACT;154
8.24.2;KEYWORDS;154
8.24.3;INTRODUCTION;154
8.24.4;EXPERIMENTAL;155
8.24.5;RESULTS;155
8.24.6;DISCUSSION;157
8.24.7;REFERENCES;157
8.25;CHAPTER 26. OZONE-INDUCED CROSS-LINKING OF ERYTHROCYTE MEMBRANE PROTEINS;158
8.25.1;ABSTRACT;158
8.25.2;KEYWORDS;158
8.25.3;INTRODUCTION;158
8.25.4;MATERIALS AND METHODS;158
8.25.5;RESULTS AND DISCUSSION;159
8.25.6;REFERENCES;161
8.26;CHAPTER 27. MEMBRANE PROTEINS OF MURINE T CELL CLONES;162
8.26.1;ABSTRACT;162
8.26.2;INTRODUCTION;162
8.26.3;MATERIALS AND METHODS;162
8.26.4;RESULTS;163
8.26.5;DISCUSSION;165
8.26.6;REFERENCES;166
8.27;CHAPTER 28. ISOLATION AND CHARACTERIZATION OF BASAL-LATERAL AND LUMINAL PLASMA-MEMBRANES FROM THE PROXIMAL TUBULE OF HUMAN KIDNEY;168
8.27.1;Introduction;168
8.27.2;Material and Methods;168
8.27.3;Results and Discussion;169
8.27.4;References;171
8.28;CHAPTER 29. FURTHER IMMUNOCHEMICAL STUDIES OF TISSUE POLYPEPTIDE ANTIGEN (TPA);172
8.28.1;ABSTRACT;172
8.28.2;KEYWORDS;172
8.28.3;INTRODUCTION;172
8.28.4;MATERIALS AND METHODS;173
8.28.5;RESULTS;173
8.28.6;CONCLUSION;174
8.28.7;REFERENCES;175
8.29;CHAPTER 30. PURIFICATION OF MEMBRANE 5' NUCLEOTIDASE PREPARATION AND PROPERTIES OF ANTI-5' NUCLEOTIDASE SERUM;176
8.29.1;ABSTRACT;176
8.29.2;KEY WORDS;176
8.29.3;INTRODUCTION;176
8.29.4;MATERIALS AND METHODS;177
8.29.5;RESULTS AND DISCUSSION;177
8.29.6;REFERENCES;179
8.30;CHAPTER 31. CHARACTERIZATION OF FOUR CHICK BRAIN SYNAPTIC MEMBRANE PROTEINS;180
8.30.1;ABSTRACT;180
8.30.2;KEYWORDS;180
8.30.3;INTRODUCTION;180
8.30.4;MATERIALS AND METHODS;180
8.30.5;RESULTS;181
8.30.6;DISCUSSION;183
8.30.7;ACKNOWLEDGEMENT;183
8.30.8;REFERENCES;183
8.31;CHAPTER 32. ISOLATION OF A MEMBRANE ANTIGEN FROM ELECTRIC ORGAN OF TORPEDO CALIFORNICA;184
8.31.1;ABSTRACT;184
8.31.2;KEYWORDS;184
8.31.3;INTRODUCTION;184
8.31.4;MATERIALS AND METHODS;185
8.31.5;RESULTS AND DISCUSSION;186
8.31.6;ACKNOWLEDGEMENT;187
8.31.7;REFERENCES;187
8.32;CHAPTER 33. CHARACTERIZATION OF SOME ANTIGENS ASSOCIATED WITH THE MEMBRANE OF HAMSTER TUMOR CELLS;188
8.32.1;ABSTRACT;188
8.32.2;KEYWORDS;188
8.32.3;INTRODUCTION;188
8.32.4;CELL LINES;188
8.32.5;ANIMALS;188
8.32.6;ANTISERA;189
8.32.7;125I-PROTEIN A BINDING ASSAY;189
8.32.8;NEUTRALIZATION WINN ASSAY;189
8.32.9;RESULTS;189
8.32.10;WINN NEUTRALIZATION TEST;190
8.32.11;DISCUSSION;191
8.32.12;REFERENCES;191
8.32.13;ACKNOWLEDGMENT;191
8.33;CHAPTER 34. NON-SPECIFIC BINDING OF (-)3H-DIHYDROALPRENOLOL TO INTACT HUMAN LYMPHOCYTES AND LYMPHOCYTE MEMBRANES;192
8.33.1;ABSTRACT;192
8.33.2;KEYWORDS;192
8.33.3;INTRODUCTION;192
8.33.4;MATERIALS AND METHODS;193
8.33.5;RESULTS;193
8.33.6;DISCUSSION;195
8.33.7;ACKNOWLEDGEMENTS;195
8.33.8;REFERENCES;195
8.34;CHAPTER 35. CHARACTERIZATION OF (-) (3H) DIHYDROALPRENOLOL BINDING SITES ON INTACT HUMAN PERIPHERAL BLOOD LYMPHOCYTES;196
8.34.1;ABSTRACT;196
8.34.2;KEYWORDS;196
8.34.3;INTRODUCTION;196
8.34.4;MATERIALS AND METHODS;196
8.34.5;RESULTS;197
8.34.6;DISCUSSION;199
8.34.7;REFERENCES;199
8.35;CHAPTER 36. STRUCTURE AND FUNCTION OF A PORE-FORMING TRANSMEMBRANE PROTEIN: HIGH RESOLUTION STUDIES OF A BACTERIAL PORIN;200
8.35.1;ABSTRACT;200
8.35.2;KEYWORDS;200
8.35.3;INTRODUCTION;200
8.35.4;MATERIALS AND METHODS;201
8.35.5;RESULTS AND DISCUSSION;202
8.35.6;ACKNOWLEDGEMENTS;202
8.35.7;REFERENCES;203
8.36;CHAPTER 37. EVIDENCE FOR PROTEIN-LIPID INTERACTIONS IN MEMBRANES OF ACHOLEPLASMA LAIDLAWII;204
8.36.1;ABSTRACT;204
8.36.2;KEYWORDS;204
8.36.3;INTRODUCTION;204
8.36.4;MATERIAL AND METHODS;204
8.36.5;RESULTS;205
8.36.6;REFERENCES;206
8.37;CHAPTER 38. ISOLATION OF SURFACE ANTIGENS FROM SCHISTOSOMA MANSONI SCHISTOSOMULA;208
8.37.1;ABSTRACT;208
8.37.2;KEYWORDS;208
8.37.3;INTRODUCTION;208
8.37.4;MATERIALS AND METHODS;209
8.37.5;RESULTS AND DISCUSSION;209
8.37.6;ACKNOWLEDGEMENTS;211
8.37.7;REFERENCES;211
8.38;CHAPTER 39. CROSSED IMMUNOELECTROPHORETIC ANALYSIS OF THE PURPLE MEMBRANE OF HALOBACTERIUM HALOBIUM;212
8.38.1;ABSTRACT;212
8.38.2;KEYWORDS;212
8.38.3;INTRODUCTION;212
8.38.4;MATERIALS AND METHODS;213
8.38.5;RESULTS;213
8.38.6;DISCUSSION;215
8.38.7;ACKNOWLEDGEMENTS;215
8.38.8;REFERENCES;215
8.39;CHAPTER 40. BETA-2-MICROGLOBULIN AND ITS ASSOCIATION WITH HISTOCOMPATIBILITY ANTIGENS OF THE MOUSE AND RABBIT;216
8.39.1;ABSTRACT;216
8.39.2;INTRODUCTION;216
8.39.3;MATERIALS AND METHODS;216
8.39.4;RESULTS AND DISCUSSION;216
8.39.5;REFERENCES;219
8.40;CHAPTER 41. EVOLUTIONARY CONSERVATION OF THE INTERACTION BETWEEN ß2-MICROGLOBULIN AND ß2-MICROGLOBULIN-BINDING MOLECULES;220
8.40.1;ABSTRACT;220
8.40.2;KEYWORDS;220
8.40.3;INTRODUCTION;220
8.40.4;MATERIALS AND METHODS;221
8.40.5;RESULTS AND DISCUSSION;221
8.40.6;ACKNOWLEDGEMENT;223
8.40.7;REFERENCES;223
8.41;CHAPTER 42. SEMINAL PLASMA LEVELS OF BETA2-MICROGLOBULIN AND CEA-LIKE PROTEIN IN INFERTILITY;224
8.41.1;ABSTRACT;224
8.41.2;KEYWORDS;224
8.41.3;INTRODUCTION;224
8.41.4;MATERIAL AND METHODS;224
8.41.5;RESULTS;225
8.41.6;DISCUSSION;227
8.41.7;REFERENCES;229
8.42;CHAPTER 43. STIMULATION OF HUMAN MONOCYTE CHEMOTAXIS BY ANTI-ß2-MICROGLOBULIN;230
8.42.1;ABSTRACT;230
8.42.2;KEYWORDS;230
8.42.3;INTRODUCTION;230
8.42.4;MATERIALS AND METHODS;231
8.42.5;RESULTS;231
8.42.6;DISCUSSION;232
8.42.7;ACKNOWLEDGEMENT;233
8.42.8;REFERENCES;233
8.43;CHAPTER 44. EXCHANGE OF ß2-MICROGLOBULIN IN HISTOCOMPATIBILITY ANTIGENS BY ITS HUMAN ANALOGUE;234
8.43.1;ABSTRACT;234
8.43.2;KEYWORDS;234
8.43.3;INTRODUCTION;234
8.43.4;MATERIALS AND METHODS;235
8.43.5;RESULTS AND DISCUSSION;235
8.43.6;ACKNOWLEDGEMENT;237
8.43.7;REFERENCES;237
8.44;CHAPTER 45. RAT SERUM COMPONENTS WITH AFFINITY FOR HUMAN B2 MICROGLOBULIN;238
8.44.1;ABSTRACT;238
8.44.2;KEYWORDS;238
8.44.3;INTRODUCTION;238
8.44.4;MATERIAL AND METHODS;238
8.44.5;RESULTS;239
8.44.6;DISCUSSION;240
8.44.7;ACKNOWLEDGMENT;241
8.44.8;REFERENCES;241
8.45;CHAPTER 46. HUMAN BLOOD GROUP M-, N-, T (THOMSEN-FRIEDENREICH)-, AND Tn-SPECIFIC LIPIDIC SUBSTANCES IN LINE-10 HEPATOCARCINOMA OF STRAIN-2 GUINEA PIGS;242
8.45.1;ABSTRACT;242
8.45.2;INTRODUCTION;242
8.45.3;MATERIALS AND METHODS;242
8.45.4;RESULTS;243
8.45.5;DISCUSSION;245
8.45.6;ACKNOWLEDGEMENT;245
8.45.7;REFERENCES;245
8.46;CHAPTER 47. FURTHER EVIDENCE THAT TERMINAL ß-GALACTOPYRANOSYL GROUPS ARE IMMUNODETERMINANT IN BLOOD GROUP N SPECIFICITY;246
8.46.1;ABSTRACT;246
8.46.2;INTRODUCTION;246
8.46.3;MATERIALS AND METHODS;247
8.46.4;RESULTS;247
8.46.5;DISCUSSION;249
8.46.6;ACKNOWLEDGEMENT;249
8.46.7;REFERENCES;249
8.47;CHAPTER 48. BIOSYNTHESIS OF HLA-A AND -B ANTIGENS;250
8.47.1;ABSTRACT;250
8.47.2;KEYWORDS;250
8.47.3;INTRODUCTION;250
8.47.4;SYNTHESIS AND MATURATION;251
8.47.5;REGULATION OF SURFACE EXPRESSION;252
8.47.6;MECHANISM OF INTRACELLULAR TRANSPORT;255
8.47.7;REFERENCES;255
8.48;CHAPTER 49. BIOCHEMICAL CHARACTERISATION OF LEUKAEMIA-ASSOCIATED CELL SURFACE ANTIGENS;256
8.48.1;ABSTRACT;256
8.48.2;KEYWORDS;256
8.48.3;INTRODUCTION;256
8.48.4;MATERIALS AND METHODS;256
8.48.5;RESULTS AND DISCUSSION;257
8.48.6;REFERENCES;259
8.49;CHAPTER 50. INFLUENCE OF SELECTIVE ABSENCE OF H-2Kk ON GROSS VIRUS LEUKAEMIAS IN VITRO AND THE IMPLICATIONS FOR IN VIVO SURVEILLANCE OF LEUKAEMIA;260
8.49.1;ABSTRACT;260
8.49.2;KEY WORDS;260
8.49.3;INTRODUCTION;260
8.49.4;MATERIALS AND METHODS;261
8.49.5;RESULTS;262
8.49.6;DISCUSSION;263
8.49.7;ACKNOWLEDGEMENT;263
8.49.8;REFERENCES;264
8.50;CHAPTER 51. PRIMARY STRUCTURAL ANALYSES OF MURINE MAJOR HISTOCOMPATIBILITY ANTIGENS;266
8.50.1;ABSTRACT;266
8.50.2;KEYWORDS;266
8.50.3;INTRODUCTION;266
8.50.4;MATERIALS AND METHOD;267
8.50.5;RESULTS AND DISCUSSION;267
8.50.6;REFERENCES;271
8.51;CHAPTER 52. CHARACTERIZATION OF DLA SD ANTIGENS USING IMMUNOCHEMICAL TECHNIQUES;272
8.51.1;ABSTRACT;272
8.51.2;KEYWORDS;272
8.51.3;INTRODUCTION;272
8.51.4;EXPERIMENTAL DESIGN AND RESULTS;273
8.51.5;ACKNOWLEDGEMENT;275
8.51.6;REFERENCES;275
8.52;CHAPTER 53. NEURON-SPECIFIC MARKERS: A CRITICAL APPRAISAL;276
8.52.1;ABSTRACT;276
8.52.2;KEYWORDS;276
8.52.3;INTRODUCTION;276
8.52.4;NEURON-SPECIFIC ENOLASE (NSE];276
8.52.5;TETANUS TOXIN (TT);278
8.52.6;THY-1;278
8.52.7;RECEPTOR FOR PHOSPHORYCHOLINE-BINDING MONOCLONAL ANTIBODIES (PC BMA);278
8.52.8;THY-2;278
8.52.9;CONCLUSION;278
8.52.10;ACKNOWLEDGEMENTS;279
8.52.11;REFERENCES;279
8.53;CHAPTER 54. VARIATIONS IN THE ANTIGENIC ARCHITECTURE OF THE ACHOLEPLASMA LAIDLAWII CELL MEMBRANE;280
8.53.1;ABSTRACT;280
8.53.2;KEYWORDS;280
8.53.3;INTRODUCTION;280
8.53.4;MATERIALS AND METHODS;280
8.53.5;RESULTS AND DISCUSSION;282
8.53.6;ACKNOWLEDGEMENT;283
8.53.7;REFERENCES;283
8.54;CHAPTER 56. INTERSPECIES CROSSREACTIVITIES OF ANTISERA DIRECTED AGAINST (Na, K)-ATPase SUBUNITS FROM BUFO MARINUS;284
8.54.1;ABSTRACT;284
8.54.2;KEYWORDS;284
8.54.3;INTRODUCTION;284
8.54.4;MATERIALS AND METHODS;284
8.54.5;RESULTS;286
8.54.6;CONCLUDING REMARKS;286
8.54.7;REFERENCES;287
8.55;CHAPTER 57. TRANSPORT OF PROTEINS INTO MITOCHONDRIA;288
8.55.1;ABSTRACT;288
8.55.2;KEYWORDS;288
8.55.3;TEXT;288
8.55.4;ACKNOWLEDGEMENT;290
8.55.5;REFERENCES;290
8.56;CHAPTER 58. THE STEREOSPECIFIC D-GLUCOSE TRANSPORT ACTIVITY OF CHOLATE EXTRACTS FROM HUMAN ERYTHROCYTE MEMBRANES. EFFECTS OF CHOLATE, EDTA AND DITHIOERYTHRITOL;292
8.56.1;ABSTRACT;292
8.56.2;KEYWORDS;292
8.56.3;INTRODUCTION;292
8.56.4;EXPERIMENTAL;293
8.56.5;RESULTS;293
8.56.6;DISCUSSION;295
8.56.7;ACKNOWLEDGEMENTS;295
8.56.8;REFERENCES;295
8.57;CHAPTER 59. SIDE-SPECIFIC TRANSFER OF MEMBRANE-BOUND PHOSPHOLIPASE A2 TO OTHER MEMBRANES BY FUSION;296
8.57.1;ABSTRACT;296
8.57.2;KEYWORDS;296
8.57.3;INTRODUCTION;296
8.57.4;EXPERIMENTAL PROCEDURE;297
8.57.5;FUSION CONDITIONS;298
8.57.6;RESULTS AND DISCUSSION;299
8.57.7;REFERENCES;299
8.58;CHAPTER 60. BILE ACID TRANSPORT IN DISTAL ILEUM;300
8.58.1;ABSTRACT;300
8.58.2;KEYWORDS;300
8.58.3;INTRODUCTION;300
8.58.4;METHODS;301
8.58.5;RESULTS;301
8.58.6;DISCUSSION;303
8.58.7;REFERENCES;303
8.59;CHAPTER 61. THE KINETICS OF INTRAMOLECULAR CROSSLINKING OF THE BAND 3 PROTEIN BY 4,4'-DIISOTHIOCYANATO DIHYDROSTILBENE-2,2'-DISULFONIC ACID (H2DIDS);304
8.59.1;ABSTRACT;304
8.59.2;KEYWORDS;304
8.59.3;REFERENCES;307
8.60;CHAPTER 62. THE EFFECT OF ARGININE SPECIFIC REAGENTS ON ANION TRANSPORT ACROSS RED BLOOD CELLS;308
8.60.1;ABSTRACT;308
8.60.2;KEYWORDS;308
8.60.3;INTRODUCTION;308
8.60.4;MATERIALS AND METHODS;308
8.60.5;RESULTS;309
8.60.6;CONCLUSION;310
8.60.7;ACKNOWLEDGEMENTS;311
8.60.8;REFERENCES;311
8.61;CHAPTER 63. DOES TERNARY COMPLEX FORMATION CONTROL THE STATE OF THE CATION BARRIER IN THE RESEALED HUMAN RED BLOOD CELL GHOST?;312
8.61.1;ABSTRACT;312
8.61.2;KEYWORDS;312
8.61.3;INTRODUCTION;312
8.61.4;METHODS;312
8.61.5;RESULTS AND DISCUSSION;313
8.61.6;REFERENCES;315
8.62;CHAPTER 64. MICROFILAMENTS AND FIBRONECTIN FIBERS INVOLVED IN THE FORMATION OF FIBROBLAST'S FOCAL CONTACTS;316
8.62.1;ABSTRACT;316
8.62.2;KEYWORDS;316
8.62.3;INTRODUCTION;316
8.62.4;RESULTS ON THE LOCATION OF FIBRONECTIN;318
8.62.5;RESULTS ON THE FUNCTION OF FIBRONECTIN IN THE ATTACHMENT OF FIBROBLASTS;318
8.62.6;ACKNOWLEDGEMENTS;319
8.62.7;REFERENCES;319
8.63;CHAPTER 65. CELL SURFACE GLYCOPROTEINS AND FIBRONECTIN MEDIATED CELL ADHESION;320
8.63.1;ABSTRACT;320
8.63.2;KEYWORDS;320
8.63.3;INTRODUCTION;320
8.63.4;METHODS;321
8.63.5;RESULTS;321
8.63.6;DISCUSSION;322
8.63.7;ACKNOWLEDGMENT;323
8.63.8;REFERENCES;323
8.64;CHAPTER 66. THE ACTIN NETWORK IN HUMAN GRANULOCYTES AT DIFFERENT STAGES OF PHAGOCYTOSIS IN GRANULOPATHIES;324
8.64.1;ABSTRACT;324
8.64.2;KEYWORDS;324
8.64.3;INTRODUCTION;324
8.64.4;MATERIALS ÄND METHODS;325
8.64.5;RESULTS;326
8.64.6;DISCUSSION;327
8.64.7;REFERENCES;327
8.65;CHAPTER 67. EXPRESSION OF FIBRONECTIN AND PLASMINOGEN ACTIVATOR IN HUMAN CELL HYBRIDS;328
8.65.1;ABSTRACT;328
8.65.2;KEYWORDS;328
8.65.3;INTRODUCTION;328
8.65.4;METHODS AND RESULTS;328
8.65.5;ACKNOWLEDGEMENTS;331
8.65.6;REFERENCES;331
8.66;CHAPTER 68. ROLE OF FIBRONECTIN DEGRADATION PRODUCTS ON CELLULAR TRANSFORMATION;332
8.66.1;ABSTRACT;332
8.66.2;KEYWORDS;332
8.66.3;INTRODUCTION;332
8.66.4;MATERIALS AND RESULTS;333
8.66.5;CONCLUSIONS;335
8.66.6;ACKNOWLEDGEMENTS;335
8.66.7;REFERENCES;335
8.67;CHAPTER 69. POSSIBLE ROLE OF THE PLASMA MEMBRANE IN REGULATING CELL GROWTH BEHAVIOUR;336
8.67.1;ABSTRACT;336
8.67.2;KEYWORDS;336
8.67.3;INTRODUCTION;336
8.67.4;EVIDENCE FOR THE PLASMA MEMBRANE TO MEDIATE CELL-GROWTH-REGULATION;337
8.67.5;A LECTIN-DERIVATIVE MIMICKING CONTACT INHIBITION OF GROWTH;338
8.67.6;INHIBITION OF EGF-INDUCED DNA SYNTHESIS BY SCA;338
8.67.7;REFERENCES;340
8.68;CHAPTER 70. INFILTRATION OF LYMPHOSARCOMA CELLS INTO HEPATOCYTE CULTURES: INHIBITION BY UNIVALENT ANTIBODIES AGAINST LIVER PLASMA MEMBRANES AND LYMPHOSARCOMA CELLS;342
8.68.1;ABSTRACT;342
8.68.2;KEYWORDS;342
8.68.3;INTRODUCTION;342
8.68.4;MATERIALS AND METHODS;343
8.68.5;RESULTS;343
8.68.6;DISCUSSION;344
8.68.7;ACKNOWLEDGEMENT;345
8.68.8;REFERENCES;345
8.69;CHAPTER 71. THE ROLE OF COMPONENTS OF THE OUTER MEMBRANE OF GRAM-NEGATIVE BACTERIA IN THE SERUM-BACTERICIDAL EFFECT;346
8.69.1;ABSTRACT;346
8.69.2;KEYWORDS;346
8.69.3;INTRODUCTION;346
8.69.4;METHODS;347
8.69.5;RESULTS;347
8.69.6;DISCUSSION;349
8.69.7;ACKNOWLEDGEMENT;349
8.69.8;REFERENCES;349
8.70;CHAPTER 72. RECEPTOR-LIGAND INTERACTION LEADING TO ENTRY OF MYXOVIRUSES INTO HOST CELLS;350
8.70.1;ABSTRACT;350
8.70.2;KEYWORDS;350
8.70.3;INTRODUCTION;350
8.70.4;RESULTS AND DISCUSSION;351
8.70.5;ACKNOWLEDGEMENT;353
8.70.6;REFERENCES;353
8.71;CHAPTER 73. MOLECULAR AGING: A TERMINATION ANTIGEN APPEARS ON SENESCENT CELLS;354
8.71.1;ABSTRACT;354
8.71.2;KEYWORDS;354
8.71.3;INTRODUCTION;354
8.71.4;MATERIALS AND METHODS;354
8.71.5;RESULTS AND DISCUSSION;355
8.71.6;REFERENCES;357
8.72;CHAPTER 74. K+ FLUXES DURING T LYMPHOCYTE ACTIVATION IN HUMAN AGING;358
8.72.1;ABSTRACT;358
8.72.2;KEYWORDS;358
8.72.3;INTRODUCTION;358
8.72.4;MATERIALS AND METHODS;359
8.72.5;RESULTS;359
8.72.6;DISCUSSION;361
8.72.7;ACKNOWLEDGEMENTS;361
8.72.8;REFERENCES;361
8.73;CHAPTER 75. AGE-RELATED DEFECT OF CYTOKINE-Ca2 + -cGMP MEDIATED TRANSMEMBRANE SIGNAL IN T LYMPHOCYTE ACTIVATION;362
8.73.1;ABSTRACT;362
8.73.2;KEYWORDS;362
8.73.3;INTRODUCTION;362
8.73.4;MATERIALS AND METHODS;363
8.73.5;RESULTS AND DISCUSSION;363
8.73.6;ACKNOWLEDGMENTS;365
8.73.7;REFERENCES;365
8.74;CHAPTER 76. SUPRAMOLECULAR ASSEMBLY OF MEMBRANE CONSTITUENTS DURING IN VITRO AGING OF HUMAN ERYTHROCYTES;366
8.74.1;ABSTRACT;366
8.74.2;KEYWORDS;366
8.74.3;INTRODUCTION;366
8.74.4;METHODS;367
8.74.5;RESULTS AND DISCUSSION;367
8.74.6;REFERENCES;369
8.75;CHAPTER 77. MASKING OF RCA I BINDING SITES BY HYALURONIC ACID IN FOETAL LIVER CELLS;370
8.75.1;ABSTRACT;370
8.75.2;INTRODUCTION;370
8.75.3;MATERIALS AND METHODS;370
8.75.4;RESULTS;371
8.75.5;DISCUSSION;372
8.75.6;ACKNOWLEDGMENTS;373
8.75.7;REFERENCES;373
8.76;CHAPTER 78. PARALLEL INCREASE OF 3-O-METHYLGLUCOSE UPTAKE AND CYTOCHALASIN B BINDING IN CHICK FIBROBLASTS DURING EMBRYO DEVELOPMENT;374
8.76.1;ABSTRACT;374
8.76.2;INTRODUCTION;374
8.76.3;MATERIALS AND METHODS;374
8.76.4;RESULTS.;375
8.76.5;DISCUSSION;376
8.76.6;ACKNOWLEDGEMENTS;377
8.76.7;REFERENCES;377
9;SECTION B: Receptor Ligand Interactions;378
9.1;CHAPTER 79. THE ACETYLCHOLINE RECEPTOR: AN ALLOSTERIC MEMBRANE PROTEIN;380
9.1.1;ABSTRACT;380
9.1.2;KEYWORDS;380
9.1.3;INTRODUCTION;380
9.1.4;ALLOSTERIC TRANSITIONS;380
9.1.5;NONCOMPETITIVE BLOCKERS;381
9.1.6;SUBUNIT STRUCTURE OF THE AcChR;384
9.1.7;ACKNOWLEDGEMENT;384
9.1.8;REFERENCES;385
9.2;CHAPTER 80. STRUCTURE AND FUNCTION OF THE HUMAN PLATELET VON WILLEBRAND FACTOR RECEPTOR;388
9.2.1;ABSTRACT;388
9.2.2;KEYWORDS;388
9.2.3;INTRODUCTION;388
9.2.4;METHODS AND MATERIALS;389
9.2.5;RESULTS AND DISCUSSION;390
9.2.6;ACKNOWLEDGEMENTS;393
9.2.7;REFERENCES;393
9.3;CHAPTER 81. STUDIES ON THE RECEPTOR SITES OF THE MONOCLONAL ANTI-Pr AND-Sa COLD AGGLUTININS;394
9.3.1;ABSTRACT;394
9.3.2;KEY WORDS;394
9.3.3;INTRODUCTION;394
9.3.4;RESULTS;395
9.3.5;DISCUSSION;396
9.3.6;ACKNOWLEDGEMENT;396
9.3.7;REFERENCES;397
9.4;CHAPTER 82. RELATIONS BETWEEN SERUM a1-FOETO-PROTEIN AND UTERINE CYTOSOL RECEPTORS IN THE IMMATURE RAT: IMPORTANCE OF FATTY ACIDS LIGANDS;398
9.4.1;ABSTRACT;398
9.4.2;KEYWORDS;398
9.4.3;INTRODUCTION;398
9.4.4;METHODS;398
9.4.5;RESULTS;399
9.4.6;CONCLUSIONS;401
9.4.7;REFERENCES;401
9.5;CHAPTER 83. SPECIFIC BINDING OF THE APO AND HOLOFORMS OF THE SERUM DBP TO THE "SOLUBLE" PART OF ACTIN FROM HUMAN LYMPHOCYTES AND PLATELETS;402
9.5.1;ABSTRACT;402
9.5.2;KEYWORDS;402
9.5.3;INTRODUCTION;402
9.5.4;MATERIAL AND METHODS;402
9.5.5;RESULTS;403
9.5.6;DISCUSSION;404
9.5.7;CONCLUSIONS;405
9.5.8;ACKNOWLEDGEMENTS;405
9.5.9;REFERENCES;405
9.6;CHAPTER 83. ACTH EFFECTS ON STEROIDOGENESIS AND ADRENAL PROTEIN SYNTHESIS: RELATION STRUCTURE-FUNCTION;406
9.6.1;ABSTRACT;406
9.6.2;KEYWORDS;406
9.6.3;INTRODUCTION;406
9.6.4;EFFECTS OF ACTH, ACTH ANALOGUES, AND dbcAMP ON TOTAL ADRENAL PROTEIN SYNTHESIS;407
9.6.5;EFFECTS OF ACTH, ACTH ANALOGUES, AND dbcAMP ON PROTEIN DEGRADATION;407
9.6.6;EFFECTS OF ACTH, ACTH ANALOGUES, AND dbcAMP ON ADRENAL SPECIFIC PROTEINS;407
9.6.7;CONCLUSIONS;409
9.6.8;ACKNOWLEDGEMENTS;409
9.6.9;REFERENCES;409
9.7;CHAPTER 84. SIMILARITIES OF THE GUANINE NUCLEOTIDE BINDING SITES RESPONSIBLE FOR ADENYLATE CYCLASE ACTIVATION AND CARBAMYLCHOLINE BINDING INHIBITION IN RAT HEART MEMBRANES;410
9.7.1;ABSTRACT;410
9.7.2;INTRODUCTION;410
9.7.3;METHODS;411
9.7.4;RESULTS AND DISCUSSION;411
9.7.5;ACKNOWLEDGEMENTS;413
9.7.6;REFERENCES;413
9.8;CHAPTER 85. STUDIES ON THE HYDROPHOBIC ANCHOR OF THE PIG INTESTINAL INTRINSIC FACTOR RECEPTOR;414
9.8.1;ABSTRACT;414
9.8.2;KEYWORDS;414
9.8.3;INTRODUCTION;414
9.8.4;MATERIAL AND METHODS;415
9.8.5;RESULTS AND DISCUSSION;415
9.8.6;ACKNOWLEDGEMENTS;417
9.8.7;REFERENCES;417
9.9;CHAPTER 86. RECEPTOR-MEDIATED ENDOCYTOSIS OF GLYCOSYLATED DERIVATIVES OF BOVINE SERUM ALBUMIN: TARGETING BASED ON SUGAR RECOGNITION;418
9.9.1;ABSTRACT;418
9.9.2;KEYWORDS;418
9.9.3;INTRODUCTION;418
9.9.4;MATERIALS AND METHODS;419
9.9.5;RESULTS;419
9.9.6;DISCUSSION;421
9.9.7;REFERENCES;421
9.9.8;ACKNOWLEDGEMENTS;421
9.10;CHAPTER 87. STRUCTURE-ACTIVITY-RELATIONSHIPS IN THE STEROIDAL 17ß-CARBOXAMIDE SERIES;422
9.10.1;ABSTRACT;422
9.10.2;KEYWORDS;422
9.10.3;INTRODUCTION;422
9.10.4;MATERIALS AND METHODS;423
9.10.5;RESULTS AND DISCUSSION;423
9.10.6;ACKNOWLEDGEMENTS;425
9.10.7;REFERENCES;425
9.11;CHAPTER 88. BINDING OF CATHEPSIN B BY HAPTOGLOBIN;426
9.11.1;ABSTRACT;426
9.11.2;KEYWORDS;426
9.11.3;INTRODUCTION;426
9.11.4;MATERIALS AND METHODS;426
9.11.5;RESULTS;427
9.11.6;DISCUSSION;429
9.11.7;REFERENCES;429
9.11.8;ACKNOWLEDGEMENT;429
9.12;CHAPTER 89. REGULATION OF THE IMMUNE RESPONSE BY THE Fc PORTION OF IMMUNOGLOBULIN;430
9.12.1;ABSTRACT;430
9.12.2;KEY WORDS;430
9.12.3;INTRODUCTION;430
9.12.4;RESULTS;431
9.12.5;DISCUSSION;433
9.12.6;REFERENCES;433
9.13;CHAPTER 90. HUMAN T-LYMPHOCYTES' Fc-RECEPTORS WITH HIGH AFFINITY FOR MONOMERIC IgG;434
9.13.1;ABSTRACT;434
9.13.2;KEY WORDS;434
9.13.3;INTRODUCTION;434
9.13.4;MATERIALS AND METHODS;434
9.13.5;RESULTS AND DISCUSSION;435
9.13.6;ACKNOWLEDGEMENTS;437
9.13.7;REFERENCES;437
9.14;CHAPTER 91. ISOLATION OF Fcy RECEPTORS RELEASED BY HUMAN LYMPHOCYTES;438
9.14.1;ABSTRACT;438
9.14.2;KEYWORDS;438
9.14.3;INTRODUCTION;438
9.14.4;MATERIAL AND METHODS;439
9.14.5;RESULTS;440
9.14.6;DISCUSSION;441
9.14.7;ACKNOWLEDGMENT;442
9.14.8;REFERENCES;443
9.15;CHAPTER 92. CYANOGEN BROMIDE FRAGMENTS OF MOUSE IgG2a AND IgG2b WHICH BIND TO THEIR Fc RECEPTORS ON MOUSE MACROPHAGES;444
9.15.1;ABSTRACT;444
9.15.2;KEYWORDS;444
9.15.3;INTRODUCTION;444
9.15.4;RESULTS AND DISCUSSION;445
9.15.5;ACKNOWLEDGMENT;447
9.15.6;REFERENCES;447
9.16;CHAPTER 93. ANTI-RECEPTOR ANTIBODIES: A COMPARISON IN THE RAT OF THE PLASMA TO BILE TRANSFER OF PURIFIED IgG, F(ab')2 AND Fab' ANTIBODIES AGAINST RAT SECRETORY COMPONENT (SC);448
9.16.1;ABSTRACT;448
9.16.2;KEYWORDS;448
9.16.3;INTRODUCTION;448
9.16.4;MATERIALS AND METHODS;448
9.16.5;RESULTS;449
9.16.6;DISCUSSION;450
9.16.7;ACKNOWLEDGEMENTS;451
9.16.8;REFERENCES;451
9.17;CHAPTER 94. RECEPTOR-MEDIATED ENDOCYTOSIS OF POLYMERIC IgA BY CULTURED RAT HEPATOCYTES;452
9.17.1;ABSTRACT;452
9.17.2;INTRODUCTION;452
9.17.3;KEYWORDS;452
9.17.4;MATERIALS AND METHODS;453
9.17.5;RESULTS;453
9.17.6;DISCUSSION;454
9.17.7;REFERENCES;455
9.18;CHAPTER 95. A NEO-ANTIGEN PRESENT ON COMPLEX a2M, RELATED TO THE RECEPTOR RECOGNITION SITE;456
9.18.1;ABSTRACT;456
9.18.2;KEYWORDS;456
9.18.3;INTRODUCTION;456
9.18.4;RESULTS;456
9.18.5;DISCUSSION;457
9.18.6;REFERENCES;458
9.19;CHAPTER 96. EVENTS INITIATED BY SOLUBLE IMMUNE COMPLEX INTERACTION WITH IMMUNOGLOBULIN RECEPTORS ON MACROPHAGES;460
9.19.1;MATERIALS AND METHODS;460
9.19.2;RESULTS AND DISCUSSION;461
9.19.3;REFERENCES;463
9.20;CHAPTER 97. MOLECULAR WEIGHT ANALYSIS OF HUMAN COMPLEMENT (C3) RECEPTORS ISOLATED BY IMMUNOPRECIPITATION;464
9.20.1;ABSTRACT;464
9.20.2;KEYWORDS;464
9.20.3;INTRODUCTION;464
9.20.4;MATERIAL AND METHODS;465
9.20.5;RESULTS AMD DISCUSSION;465
9.20.6;ACKNOWLEDGEMENT;466
9.20.7;REFERENCES;466
9.21;CHAPTER 98. THE RECEPTOR FUNCTIONS OF ENDOGENOUS Clq, A SUBCOMPONENT OF THE FIRST COMPONENT OF COMPLEMENT, ON PERITONEAL MACROPHAGES;468
9.21.1;ABSTRACT;468
9.21.2;KEYWORDS;468
9.21.3;INTRODUCTION;468
9.21.4;MATERIAL AND METHODS;469
9.21.5;RESULTS AND DISCUSSION;469
9.21.6;ACKNOWLEDGEMENT;471
9.21.7;REFERENCES;471
9.22;CHAPTER 99. RECEPTORS FOR C3b, C3bi, C3d AND ß1H ON LYMPHOCYTES AND PHAGOCYTIC CELLS;472
9.22.1;ACKNOWLEDGEMENT;473
9.22.2;REFERENCES;473
9.23;CHAPTER 100. EVIDENCE FOR ENDOCYTOSIS OF IRON LOADED TRANSFERRIN BY CULTURED RAT EMBRYO FIBROBLASTS;476
9.23.1;ABSTRACT;476
9.23.2;KEYWORDS;476
9.23.3;INTRODUCTION;476
9.23.4;MATERIALS AND METHODS;477
9.23.5;RESULTS;477
9.23.6;DISCUSSION;479
9.23.7;REFERENCES;479
9.24;CHAPTER 101. TRANSFERRIN RECEPTORS IN TRANSFORMATION AND DIFFERENTIATION;480
9.24.1;ABSTRACT;480
9.24.2;KEYWORDS;480
9.24.3;INTRODUCTION;480
9.24.4;MATERIALS AND METHODS;480
9.24.5;RESULTS;481
9.24.6;DISCUSSION;482
9.24.7;ACKNOWLEDGEMENTS;482
9.24.8;REFERENCES;482
9.25;CHAPTER 102. MEDIATION OF A RECEPTORMECHANISM IN THE UPTAKE OF IRON FROM TRANSFERRIN BY THE HEPATOCYTE;484
9.25.1;ABSTRACT;484
9.25.2;KEYWORDS;484
9.25.3;INTRODUCTION;484
9.25.4;MATERIALS AND METHODS;484
9.25.5;RESULTS;485
9.25.6;DISCUSSION;486
9.25.7;REFERENCES;487
9.26;CHAPTER 103. IRON UPTAKE BY CHINESE HAMSTER FIBROBLASTS FROM HUMAN TRANSFERRIN;488
9.26.1;ABSTRACT;488
9.26.2;KEYWORDS;488
9.26.3;INTRODUCTION;488
9.26.4;EXPERIMENTAL;488
9.26.5;RESULTS AND DISCUSSION;489
9.26.6;REFERENCES;491
9.27;CHAPTER 104. RECEPTOR-MEDIATED ENDOCYTOSIS OF HEME-HEMOPEXIN BY RAT HEPATOCYTES;492
9.27.1;ABSTRACT;492
9.27.2;KEYWORDS;492
9.27.3;INTRODUCTION;492
9.27.4;MATERIALS AND METHODS;492
9.27.5;RESULTS;493
9.27.6;DISCUSSION;494
9.27.7;REFERENCES;495
9.28;CHAPTER 105. SPECTRAL AND OTHER STUDIES ON THE INTESTINAL HEME RECEPTOR OF THE PIG;496
9.28.1;ABSTRACT;496
9.28.2;KEYWORDS;496
9.28.3;INTRODUCTION;496
9.28.4;MATERIAL AND METHODS;497
9.28.5;RESULTS AND DISCUSSION;497
9.28.6;ACKNOWLEDGEMENT;499
9.28.7;REFERENCES;499
9.29;CHAPTER 106. DIFFERENTIATION BETWEEN STERESPECIFIC BINDING SITES ON A DOPAMINE RECEPTOR COMPLEX: EFFECTS OF PROTEOLYTIC ENZYMES;500
9.29.1;ABSTRACT;500
9.29.2;KEYWORDS;500
9.29.3;INTRODUCTION;500
9.29.4;MATERIALS AND METHODS;501
9.29.5;RESULTS;501
9.29.6;DISCUSSION;504
9.29.7;REFERENCES;505
9.30;CHAPTER 107. BIOCHEMICAL AND PHARMACOLOGICAL STUDIES OF SUBSTANCE P RECEPTORS;506
9.30.1;ABSTRACT;506
9.30.2;KEYWORDS;506
9.30.3;INTRODUCTION;506
9.30.4;RAT BRAIN BINDING;507
9.30.5;RAT SALIVARY GLANDS: LIPID TURNOVER, a-AMYLASE RELEASE AND IN VIVO SALIVATION;508
9.30.6;EVIDENCE FOR MULTIPLE SUBSTANCE P RECEPTORS;509
9.30.7;ACKNOWLEDGEMENT;511
9.30.8;REFERENCES;511
9.31;CHAPTER 108. NEUROTENSIN-RECEPTOR INTERACTIONS: BINDING AND PHARMACOLOGICAL STUDIES; BIOLOGICAL RELEVANCE; STRUCTURE-ACTIVITY RELATIONSHIPS;512
9.31.1;ABSTRACT;512
9.31.2;KEYWORDS;512
9.31.3;INTRODUCTION;512
9.31.4;RADIORECEPTORASSAYS FOR NT;513
9.31.5;STRUCTURE-ACTIVITY STUDIES;513
9.31.6;CONCLUSIONS;515
9.31.7;ACKNOWLEDGEMENTS;515
9.31.8;REFERENCES;515
9.32;CHAPTER 109. A NOVEL TRIAZOLOPYRIDAZINE, 3H-CL 218, 872 WHICH LABELS THE BENZODIAZEPINE RECEPTOR IN RAT BRAIN;516
9.32.1;ABSTRACT;516
9.32.2;KEYWORDS;516
9.32.3;INTRODUCTION;516
9.32.4;METHODS;516
9.32.5;RESULTS AND DISCUSSION;517
9.32.6;ACKNOWLEDGEMENTS;520
9.32.7;REFERENCES;520
9.33;CHAPTER 110. IMMUNOLOGICAL STUDIES OF ß ADRENERGIC CATECHOLAMINE RECEPTORS: A TWO-WAY APPROACH;522
9.33.1;ABSTRACT;522
9.33.2;INTRODUCTION;522
9.33.3;MATERIALS AND METHODS;522
9.33.4;RESULTS AND DISCUSSION;523
9.33.5;ACKNOWLEDGEMENTS;525
9.33.6;REFERENCES;525
9.34;CHAPTER 111. ASYMMETRY OF ACETYLCHOL-INESTERASE AND ACETYLCHOLINE RECEPTOR IN INTACT SECRETORY VESICLES FROM ADRENAL MEDULLA;526
9.34.1;ABSTRACT;526
9.34.2;KEYWORDS;526
9.34.3;INTRODUCTION;526
9.34.4;RESULTS AND DISCUSSION;526
9.34.5;ACKNOWLEDGMENT;529
9.34.6;REFERENCES;529
9.35;CHAPTER 112. LOSS OF ß2-ADRENOCEPTORS AFTER HAEMOPHILUS INFLUENZAE VACCINATION;530
9.35.1;ABSTRACT;530
9.35.2;KEYWORDS;530
9.35.3;INTRODUCTION;530
9.35.4;METHODS;530
9.35.5;RESULTS;531
9.35.6;DISCUSSION;532
9.35.7;ACKNOWLEDGEMENTS;533
9.35.8;REFERENCES;533
9.36;CHAPTER 113. CHARACTERIZATION OF ADRENERGIC BINDING IN CANINE LUNG TISSUE;534
9.36.1;ABSTRACT;534
9.36.2;KEYWORDS;534
9.36.3;INTRODUCTION;534
9.36.4;METHODS;535
9.36.5;RESULTS;535
9.36.6;DISCUSSION;537
9.36.7;REFERENCES;537
9.36.8;ACKNOWLEDGEMENT;537
9.37;CHAPTER 114. HETEROGENEITY OF VIP-SECRETIN RECEPTORS IN THREE RAT TISSUES;538
9.37.1;ABSTRACT;538
9.37.2;INTRODUCTION;538
9.37.3;MATERIALS AND METHODS;538
9.37.4;RESULTS;539
9.37.5;CONCLUSION;541
9.37.6;ACKNOWLEDGMENTS;541
9.37.7;REFERENCES;541
9.38;CHAPTER 115. VASOACTIVE INTESTINAL PEPTIDE (VIP) CONTROL OF CYCLIC AMP ACCUMULATION IN DIGESTIVE EPITHELIA: INVOLVEMENT OF MULTIPLE REGULATORY PROCESSES;542
9.38.1;1°) The recognition site;542
9.38.2;2°) The coupling between VIP receptors and adenylate cyclase;544
9.38.3;3°) The phosphodiesterase activity;544
9.38.4;REFERENCES;545
9.39;CHAPTER 116. EFFECTS OF GTP ON VASOPRESSIN, AND ANGIOTENSIN BINDING TO RAT LIVER MEMBRANES;546
9.39.1;ABSTRACT;546
9.39.2;KEYWORDS;546
9.39.3;INTRODUCTION;546
9.39.4;MATERIALS AND METHODS;546
9.39.5;RESULTS;547
9.39.6;CONCLUSIONS;548
9.39.7;REFERENCES;549
9.40;CHAPTER 117. CHOLECYSTOKIN IN IN BRAIN AND HYPOPHYSIS;550
9.40.1;ABSTRACT;550
9.40.2;KEYWORDS;550
9.40.3;DISCOVERY OF DIGESTIVE PEPTIDES IN THE CENTRAL NERVOUS SYSTEM;550
9.40.4;IDENTIFICATION OF CCK IN THE CENTRAL NERVOUS SYSTEM AND THE NEUROHYPOPHYSIS;550
9.40.5;CHARACTERISTICS OF CCK IN THE CENTRAL NERVOUS SYSTEM AND HYPOPHYSIS;552
9.40.6;DISTRIBUTION OF CCK IN THE CENTRAL NERVOUS SYSTEM AND THE NEUROHYPOPHYSIS;552
9.40.7;CORTICAL AND LIMBIC SYSTEMS;552
9.40.8;MESENCEPHALIC SYSTEM;552
9.40.9;SENSITIVE SYSTEM;554
9.40.10;CONCLUSIONS;554
9.40.11;ACKNOWLEDGMENT;554
9.40.12;REFERENCES;554
9.41;CHAPTER 118. VASOACTIVE INTESTINAL POLYPEPTIDE (VIP): SPECIFIC RECEPTORS ON SMOOTH MUSCLE MEMBRANES FROM PORCINE UTERUS;556
9.41.1;ABSTRACT;556
9.41.2;KEYWORDS;556
9.41.3;INTRODUCTION;556
9.41.4;METHODS;556
9.41.5;RESULTS;557
9.41.6;DISCUSSION;558
9.41.7;ACKNOWLEDGEMENTS;558
9.41.8;REFERENCES;559
9.42;CHAPTER 119. IMPAIRED SECRETIN-VIP SENSITIVITY OF ADENYLATE CYCLASE IN THE HEART OF CONGENITALLY HYPERTENSIVE (SHR) OR OBESE (fa/fa) RATS;560
9.42.1;ABSTRACT;560
9.42.2;MATERIALS AND METHODS;560
9.42.3;RESULTS;561
9.42.4;DISCUSSION;562
9.42.5;REFERENCES;563
9.43;CHAPTER 120. MULTIPLE FUNCTIONS OF PEPTIDES: INSULIN AND VASOACTIVE INTESTINAL POLYPEPTIDE BIND TO RECEPTORS IN LIVER AND BRAIN;564
9.43.1;ABSTRACT;564
9.43.2;KEYWORDS;564
9.43.3;INTRODUCTION;564
9.43.4;METHODS;565
9.43.5;RESULTS;565
9.43.6;VIP Receptors;566
9.43.7;DISCUSSION;566
9.43.8;ACKNOWLEDGMENTS;567
9.43.9;REFERENCES;567
9.44;CHAPTER 121. THE COMPLEX KINETICS OF INSULIN BINDING TO RECEPTORS ON ISOLATED PIG HEPATOCYTES;568
9.44.1;ABSTRACT;568
9.44.2;KEYWORDS;568
9.44.3;INTRODUCTION;568
9.44.4;METHODS;569
9.44.5;RESULTS;569
9.44.6;DISCUSSION;570
9.44.7;ACKNOWLEDGEMENT;571
9.44.8;REFERENCES;571
9.45;CHAPTER 122. IN VIVO STUDIES BY GAMMA-CAMERA OF131 I-INSULIN DISTRIBUTION AND METABOLISM IN RABBITS;572
9.45.1;ABSTRACT;572
9.45.2;KEYWORDS;572
9.45.3;INTRODUCTION;572
9.45.4;MATERIALS AND METHODS;573
9.45.5;RESULTS AND DISCUSSION;574
9.45.6;REFERENCES;575
9.46;CHAPTER 123. IMMUNOHISTOCHEMICAL AND AUTORADIOGRAPHIC VISUALIZATION OF PORCINE AND HUMAN 125 I-INSULIN HEPATIC BINDING IN VIVO;576
9.46.1;ABSTRACT;576
9.46.2;KEYWORDS;576
9.46.3;INTRODUCTION;576
9.46.4;MATERIALS AND METHODS;576
9.46.5;RESULTS AND DISCUSSION;577
9.46.6;ACKNOWLEDGEMENTS;579
9.46.7;REFERENCES;579
9.47;CHAPTER 124. VARIATION OF a-MSH RECEPTIVITY BETWEEN MALIGNANT MELANOCYTES FROM HORIZONTAL AND VERTICAL GROWTH PHASES IN A HUMAN SUPERFICIAL SPREADING MELANOMA;580
9.47.1;ABSTRACT;580
9.47.2;KEYWORDS;580
9.47.3;INTRODUCTION;580
9.47.4;MATERIALS AND METHODS;580
9.47.5;RESULTS;581
9.47.6;DISCUSSION;581
9.47.7;REFERENCES;583
9.48;CHAPTER 125. 125 I-a-MSH BINDING IN HUMAN MELANOMA CELL LINES;584
9.48.1;ABSTRACT;584
9.48.2;KEYWORDS;584
9.48.3;INTRODUCTION;584
9.48.4;MATERIALS AND METHODS;585
9.48.5;RESULTS AND DISCUSSION;586
9.48.6;REFERENCES;587
9.49;CHAPTER 126. DNA REPLICATION AND PRODUCTION OF RETROVIRAL MARKERS IN HUMAN MELANOMA CULTURES DEPENDS ON DEGREE OF DIFFERENTIATION AND ON HORMONAL STIMULATION;588
9.49.1;ABSTRACT;588
9.49.2;KEYWORDS;588
9.49.3;INTRODUCTION;588
9.49.4;MATERIALS AND METHODS;589
9.49.5;RESULTS AND DISCUSSION;590
9.49.6;REFERENCES;591
9.50;CHAPTER 127. BINDING OF ENDOGENOUS a-MSH TO MALIGNANT MELANOCYTES IN HUMAN MELANOMAS;592
9.50.1;ABSTRACT;592
9.50.2;KEYWORDS;592
9.50.3;INTRODUCTION;592
9.50.4;MATERIALS AND METHODS;592
9.50.5;RESULTS;593
9.50.6;DISCUSSION;593
9.50.7;REFERENCES;595
9.51;CHAPTER 128. HORMONAL SCREENING IN PATIENTS SUFFERING MALIGNANT MELANOMA. A PRELIMINARY APPROACH;596
9.51.1;ABSTRACT;596
9.51.2;KEYWORDS;596
9.51.3;INTRODUCTION;596
9.51.4;MATERIALS AND METHODS;597
9.51.5;RESULTS AND DISCUSSION;597
9.51.6;REFERENCES;599
9.52;CHAPTER 129. ANTIBODIES AGAINST TSH RECEPTOR IN GRAVES' DISEASE: EVALUATION BY RELEASE OF c600
9.52.1;INTRODUCTION;600
9.52.2;MATERIALS AND METHODS;601
9.52.3;RESULTS;602
9.52.4;DISCUSSION;603
9.52.5;ACKNOWLEDGEMENT;603
9.52.6;REFERENCES;603
9.53;CHAPTER 130. ANTIBODIES AGAINST TSH RECEPTOR IN GRAVES' DISEASE: RELATION BETWEEN cGMP/cAMP RELEASE;604
9.53.1;INTRODUCTION;604
9.53.2;MATERIALS AND METHODS;605
9.53.3;RESULTS;605
9.53.4;DISCUSSION;606
9.53.5;ACKNOWLEDGEMENT;607
9.53.6;REFERENCES;607
9.54;CHAPTER 131. NEGATIVE CONTROLS OF DOG THYROID ADENYLATE CYCLASE CYCLIC AMP SYSTEM;608
9.54.1;REFERENCES;610
9.55;CHAPTER 132. RAT LIVER GLUCOCORTICOID RECEPTOR PURIFIED IN PRESENCE OF MOLYBDATE;612
9.55.1;ABSTRACT;612
9.55.2;KEYWORDS;612
9.55.3;INTRODUCTION;612
9.55.4;RESULTS and DISCUSSION;613
9.55.5;AKNOWLEDGMENTS;615
9.55.6;REFERENCES;615
9.56;CHAPTER 133. INDUCTION OF PROLACTIN LIVER RECEPTORS IN THE MALE RAT;616
9.56.1;ABSTRACT;616
9.56.2;KEY WORDS;616
9.56.3;INTRODUCTION;616
9.56.4;MATERIALS AND METHODS;617
9.56.5;RESULTS;617
9.56.6;DISCUSSION;619
9.56.7;REFERENCES;619
9.57;CHAPTER 134. AN AFFINITY ADSORBENT FOR AN ESTROGEN BINDING PROTEIN RAT a-FETOPROTEIN;620
9.57.1;ABSTRACT;620
9.57.2;KEYWORDS;620
9.57.3;MATERIALS AND METHODS;620
9.57.4;RESULTS AND DISCUSSION;621
9.57.5;ACKNOWLEDGEMENTS;623
9.57.6;REFERENCES;623
9.58;CHAPTER 135. RECEPTORS FOR REGULATORY PEPTIDES IN EPITHELIAL GUT CANCER;624
9.58.1;ABSTRACT;624
9.58.2;KEYWORDS;624
9.58.3;INTRODUCTION;624
9.58.4;RESULTS AND DISCUSSION;624
9.58.5;CONCLUSION;626
9.58.6;REFERENCES;627
9.59;CHAPTER 136. RECEPTORS THAT CONTROL ACID SECRETION IN THE ISOLATED CELLSFROM MAMMALIAN GASTRIC MUCOSA;628
9.59.1;ABSTRACT;628
9.59.2;KEYWORDS;628
9.59.3;INTRODUCTION;628
9.59.4;MATERIALS AND METHODS;628
9.59.5;RESULTS;629
9.59.6;DISCUSSION;631
9.59.7;REFERENCES;631
9.60;CHAPTER 137. MICROBIAL RECEPTORS ON HUMANKIDNEY EPITHELIA, A POSSIBLE CLUEIN THE PATHOGENESIS OF BACTERIALINTERSTITIAL NEPHRITIS;632
9.60.1;Introduction;632
9.60.2;Material;632
9.60.3;Methods;633
9.60.4;Results and Discussion;633
9.60.5;References;635
10;SECTION C: Monoclonal Antibodies;636
10.1;CHAPTER 138.
HUMAN-MOUSE HYBRIDOMA CELLS PRODUCING ANTIBODIES;638
10.1.1;ABSTRACT;638
10.1.2;KEYWORDS;638
10.1.3;INTRODUCTION;638
10.1.4;MATERIALS AND METHODS;639
10.1.5;RESULTS;639
10.1.6;DISCUSSION;641
10.1.7;ACKNOWLEDGEMENT;642
10.1.8;REFERENCES;643
10.2;CHAPTER 139. PRODUCTION OF RAT MONOCLONAL ANTIBODIES WITH THE LOU RAT NON SECRETING IR983F MYELOMA CELL LINE;644
10.2.1;ABSTRACT;644
10.2.2;KEYWORDS;644
10.2.3;INTRODUCTION;644
10.2.4;ORIGIN OF THE LOU STRAIN;645
10.2.5;ILEOCAECAL NALIGNANT IMMUNOCYTOMAS;645
10.2.6;BIOSYNTHESIS OF RAT MONOCLONAL IMMUNOGLOBULINS;645
10.2.7;RAT-RAT HYBRIDOMAS;645
10.2.8;REFERENCES;647
10.3;CHAPTER 140. ANTI-Pr, -Gd AND RELATED COLD AGGLUTININS: HUMAN MONOCLONAL ANTIBODIES AGAINST NEURAMINYL GROUPS;648
10.3.1;ABSTRACT;648
10.3.2;KEYWORDS;648
10.3.3;INTRODUCTION;648
10.3.4;SEROLOGIC DETERMINATION OF ANTI-Pr, -Gd AND RELATED CA;649
10.3.5;IMMUNOCHEMISTRY OF Pr, Gd AND RELATED ANTIGENS;649
10.3.6;DISCUSSION;651
10.3.7;REFERENCES;651
10.4;CHAPTER 141. ANALYSIS OF CARBOHYDRATE DETERMINANTS ON MEMBRANES OF LEUKEMIC LEUKOCYTES USING NATURALLY OCCURRING MONOCLONAL HUMAN ANTIBODIES (COLD AGGLUTININS);652
10.4.1;ABSTRACT;652
10.4.2;KEYWORDS;652
10.4.3;INTRODUCTION;652
10.4.4;MATERIAL AND METHODS;653
10.4.5;RESULTS AND DISCUSSION;653
10.4.6;REFERENCES;655
10.5;CHAPTER 142. A STUDY OF HYBRIDOMA SOFT AGAR CLONING;656
10.5.1;ABSTRACT;656
10.5.2;KEYWORDS;656
10.5.3;INTRODUCTION;656
10.5.4;MATERIAL AND METHODS;657
10.5.5;RESULTS;657
10.5.6;CONCLUSIONS;658
10.5.7;REFERENCES;659
10.5.8;ACKNOWLEDGEMENTS;659
10.6;CHAPTER 143. EVALUATION OF ALTERNATIVE SCREENING AND SELECTION PROCEDURES IN HYBRIDOMA TECHNOLOGY;660
10.6.1;ABSTRACT;660
10.6.2;KEYWORDS;660
10.6.3;INTRODUCTION;660
10.6.4;MATERIALS AND METHODS;661
10.6.5;RESULTS;661
10.6.6;REFERENCES;664
10.7;CHAPTER 144. COMPARISON OF SCREENING TECHNIQUES RELATED TO THE PRODUCTION OF MONOCLONAL ANTIBODIES;666
10.7.1;ABSTRACT;666
10.7.2;KEYWORDS;666
10.7.3;INTRODUCTION;666
10.7.4;MATERIALS AND METHODS;667
10.7.5;RESULTS;668
10.7.6;CONCLUSIONS;669
10.7.7;ACKNOWLEDGMENTS;669
10.7.8;REFERENCES;669
10.8;CHAPTER 145. A SEMI-AUTOMATED ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) TO SCREEN FOR HYBRIDOMA CULTURES PRODUCING ANTIBODY TO CARCINOEMBRYONIC ANTIGEN;670
10.8.1;ABSTRACT;670
10.8.2;INTRODUCTION;670
10.8.3;MATERIALS AND METHODS;670
10.8.4;RESULTS;672
10.8.5;DISCUSSION;673
10.8.6;ACKNOWLEDGEMENT;673
10.8.7;REFERENCES;673
10.9;CHAPTER 146. SELECTION OF MYELOMA LINES SUITABLE FOR HYBRIDOMA;674
10.9.1;ABSTRACT;674
10.9.2;KEYWORDS;674
10.9.3;INTRODUCTION;674
10.9.4;MATERIAL AND METHODS;675
10.9.5;RESULTS AND DISCUSSION;676
10.9.6;ACKNOWLEDGEMENTS;677
10.9.7;REFERENCES;677
10.10;CHAPTER 147. INDIVIDUAL PHYSICAL PROPERTIES OF MOUSE MONOCLONAL ANTIBODIES;678
10.10.1;ABSTRACT;678
10.10.2;KEYWORDS;678
10.10.3;INTRODUCTION;678
10.10.4;MATERIALS;678
10.10.5;METHODS;679
10.10.6;THEORETICAL CONSIDERATIONS;679
10.10.7;RESULTS;680
10.10.8;DISCUSSION;681
10.10.9;ACKNOWLEDGEMENTS;681
10.10.10;REFERENCES;681
10.11;CHAPTER 148. RE-DEFINITION OF HUMAN T CELLS BY MONOCLONAL ANTIBODIES;682
10.11.1;ABSTRACT;682
10.11.2;KEYWORDS;682
10.11.3;INTRODUCTION;682
10.11.4;MATERIALS AND METHODS;683
10.11.5;RESULTS AND DISCUSSION;683
10.11.6;ACKNOWLEDGMENT;686
10.11.7;REFERENCES;686
10.12;CHAPTER 149. BIOCHEMICAL STUDIES OF HUMAN T CELL MARKERS;688
10.12.1;ABSTRACT;688
10.12.2;KEYWORDS;688
10.12.3;INTRODUCTION;688
10.12.4;RESULTS AND DISCUSSION;689
10.12.5;REFERENCES;691
10.13;CHAPTER 150. MOUSE MONOCLONAL ANTIBODIES DEFINING FUNCTIONAL HUMAN LYMPHOCYTE SUBSETS;692
10.13.1;ABSTRACT;692
10.13.2;KEY WORDS;692
10.13.3;INTRODUCTION;692
10.13.4;MATERIAL AND METHODS;692
10.13.5;RESULTS AND DISCUSSION;693
10.13.6;ACKNOWLEDGEMENT;695
10.13.7;REFERENCES;695
10.14;CHAPTER 151. T-CELL PROFILE AND REACTIVITY IN VITRO DURING IMMUNE RECONSTITUTION FOLLOWING BONE MARROW TRANSPLANTATION;696
10.14.1;ABSTRACT;696
10.14.2;KEYWORDS;696
10.14.3;INTRODUCTION;696
10.14.4;MATERIALS AND METHODS;696
10.14.5;RESULTS;697
10.14.6;DISCUSSION;699
10.14.7;REFERENCES;699
10.15;CHAPTER 152. INTERACTION OF MONOCLONAL ANTIBODIES AND ANTIGEN-SPECIFIC T-CELL FACTOR IN REGULATION OF AN IMMUNE RESPONSE;700
10.15.1;ABSTRACT;700
10.15.2;KEYWORDS;700
10.15.3;INTRODUCTION;700
10.15.4;MATERIALS AND METHODS;700
10.15.5;RESULTS;701
10.15.6;DISCUSSION;702
10.15.7;REFERENCES;702
10.16;CHAPTER 153. MICROFLUOROMETRIC ANALYSIS OF FIVE MONOCLONAL ANTIBODIES DIRECTED AGAINST MOUSE THYMOCYTES;704
10.16.1;ABSTRACT;704
10.16.2;KEYWORDS;704
10.16.3;INTRODUCTION;704
10.16.4;MATERIALS AND METHODS;704
10.16.5;RESULTS AND DISCUSSION;706
10.16.6;REFERENCES;707
10.17;CHAPTER 154. BINDING CHARACTERISTICS OF A MONOCLONAL ANTIBODY AGAINST RABBIT THYMOCYTES;708
10.17.1;ABSTRACT;708
10.17.2;KEYWORDS;708
10.17.3;INTRODUCTION;708
10.17.4;MATERIALS AND METHODS;708
10.17.5;RESULTS;709
10.17.6;DISCUSSION;711
10.17.7;ACKNOWLEDGEMENTS;711
10.17.8;REFERENCES;711
10.18;CHAPTER 155. ABNORMAL HELPER/SUPPRESSOR T-CELL DISTRIBUTION IN CHRONIC BRUCELLOSIS IN HUMANS;712
10.18.1;ABSTRACT;712
10.18.2;KEYWORDS;712
10.18.3;INTRODUCTION;712
10.18.4;MATERIALS AND METHODS;712
10.18.5;RESULTS;713
10.18.6;DISCUSSION;715
10.18.7;REFERENCES;715
10.19;CHAPTER 156. MONOCLONAL ANTIBODIES DEFINING RABBIT LYMPHOCYTE SUBPOPULATIONS;716
10.19.1;ABSTRACT;716
10.19.2;KEYWORDS;716
10.19.3;INTRODUCTION;716
10.19.4;MATERIALS AND METHODS;716
10.19.5;RESULTS AND DISCUSSION;717
10.19.6;ACKNOWLEDGEMENTS;719
10.19.7;REFERENCES;719
10.20;CHAPTER 157. THE USE OF MONOCLONAL ANTIBODIES TO MONITOR T-CELL SUB-POPULATIONS AFTER HUMAN CARDIAC TRANSPLANTATION;720
10.20.1;ABSTRACT;720
10.20.2;KEYWORDS;720
10.20.3;INTRODUCTION;720
10.20.4;PATIENTS AND METHOD;720
10.20.5;RESULTS AND DISCUSSION;721
10.20.6;ACKNOWLEDGEMENT;723
10.20.7;REFERENCES;723
10.20.8;ADDENDUM;723
10.21;CHAPTER 158. MONOCLONAL ANTI-B CELLANTIBODIES: THEIR EFFECTS ON HUMAN MIXED LYMPHOCYTE REACTIONS;724
10.21.1;KEYWORDS;724
10.21.2;ABSTRACT;724
10.21.3;INTRODUCTION;724
10.21.4;METHODS;725
10.21.5;FINDINGS;725
10.21.6;Conclusions;727
10.21.7;Acknowledgements;728
10.21.8;REFERENCES;728
10.22;CHAPTER 159. MONOCLONAL ANTIBODIES AGAINST HUMAN THYMOCYTES AND T LYMPHOCYTES;730
10.22.1;ABSTRACT;730
10.22.2;INTRODUCTION;730
10.22.3;MATERIALS AND METHODS;730
10.22.4;RESULTS AND DISCUSSION;731
10.22.5;ACKNOWLEDGEMENTS;733
10.22.6;REFERENCES;733
10.23;CHAPTER 160. MONOCLONAL ANTIBODIES AGAINST RAT THYMOCYTES;734
10.23.1;ABSTRACT;734
10.23.2;KEYWORDS;734
10.23.3;INTRODUCTION;734
10.23.4;MATERIALS AND METHODS;734
10.23.5;RESULTS;735
10.23.6;DISCUSSION;736
10.23.7;ACKNOWLEDGEMENTS;737
10.23.8;REFERENCES;737
10.24;CHAPTER 161. MONOCLONAL ANTIBODIES AGAINST HUMAN MHC PRODUCTS;738
10.24.1;ABSTRACT;738
10.24.2;KEYWORDS;738
10.24.3;INTRODUCTION;738
10.24.4;RESULTS AND DISCUSSION;738
10.24.5;REFERENCES;741
10.25;CHAPTER 162. BIOCHEMICAL ANALYSIS OF HUMAN HLA-DR MOLECULES;742
10.25.1;ABSTRACT;742
10.25.2;INTRODUCTION;742
10.25.3;MATERIALS AND METHODS;742
10.25.4;RESULTS AND DISCUSSION;743
10.25.5;REFERENCES;746
10.26;CHAPTER 162. FUNCTIONAL ANALYSIS OF HUMAN la SUBSETS;748
10.26.1;ABSTRACT;748
10.26.2;KEYWORDS;748
10.26.3;MATERIALS AND METHODS;748
10.26.4;RESULTS;749
10.26.5;DISCUSSION;750
10.26.6;REFERENCES;751
10.27;CHAPTER 163. REACTIVITY OF MONOCLONAL ANTL-HLA ANTIBODIES WITH BLOOD PLATELETS;752
10.27.1;ABSTRACT;752
10.27.2;KEYWORDS;752
10.27.3;INTRODUCTION;752
10.27.4;MATERIALS AND METHODS;754
10.27.5;RESULTS;755
10.27.6;DISCUSSION;755
10.27.7;ACKNOWLEDGEMENTS;756
10.27.8;REFERENCES;756
10.28;CHAPTER 164. SUBSETS OF HUMAN D LOCUS PRODUCTS IDENTIFIED BY A SERIES OF MONOCLONAL ANTIBODIES;758
10.28.1;ABSTRACT;758
10.28.2;KEYWORDS;758
10.28.3;INTRODUCTION;758
10.28.4;MATERIALS AND METHODS;759
10.28.5;RESULTS AND DISCUSSION;760
10.28.6;CONCLUSIONS;763
10.28.7;ACKNOWLEDGEMENTS;763
10.28.8;REFERENCES;763
10.29;CHAPTER 165. MONOCLONAL ANTIBODIES DETECTING EPSTEIN-BARR VIRUS STRAIN AND GROUP SPECIFIC ANTIGENIC DETERMINANTS;764
10.29.1;ABSTRACT;764
10.29.2;KEYWORDS;764
10.29.3;INTRODUCTION;764
10.29.4;MATERIALS AND METHODS;765
10.29.5;RESULTS AND DISCUSSION;765
10.29.6;ACKNOWLEDGEMENTS;767
10.29.7;REFERENCES;767
10.30;CHAPTER 166. MONOCLONAL ANTIBODY AGAINSTEBV-ASSOCIATED TRANSFORMATIONANTIGEN DETECTED IN VITRO ANDIN VIVO;768
10.30.1;ABSTRACT;768
10.30.2;KEYWORDS;768
10.30.3;INTRODUCTION;768
10.30.4;RESULTS;768
10.30.5;REFERENCES;771
10.31;CHAPTER 167. PRODUCTION OF MONOCLONAL ANTIBODIES AGAINST POLIOMYELITIS AND RABIES VIRUSES;772
10.31.1;ABSTRACT;772
10.31.2;KEYWORDS;772
10.31.3;INTRODUCTION;772
10.31.4;IMMUNIZATION, FUSION AND SCREENING;772
10.31.5;MONOCLONAL ANTIBODIES AGAINST POLIO VIRUS I SUBTYPES;773
10.31.6;MONOCLONAL ANTIBODIES AGAINST RABIES VIRUS;774
10.31.7;ACKNOWLEDGEMENTS;775
10.31.8;REFERENCES;775
10.32;CHAPTER 168. A SET OF MONOCLONAL ANTIBODIES TO STREPTOCOCCAL GROUP POLYSACCHARIDE ANTIGENS;776
10.32.1;ABSTRACT;776
10.32.2;KEYWORDS;776
10.32.3;INTRODUCTION;776
10.32.4;MATERIALS AND METHODS;776
10.32.5;RESULTS AND DISCUSSION;777
10.32.6;ACKNOWLEDGEMENT;779
10.32.7;REFERENCES;779
10.33;CHAPTER 169. HYBRIDOMA ANTIBODY MEDIATED ACTIVATION OF ß-GALACTOSIDASES FROM GENETICALLY DEFECTIVE E. COLI;780
10.33.1;ABSTRACT;780
10.33.2;KEYWORDS;780
10.33.3;INTRODUCTION;780
10.33.4;MATERIALS AND METHODS;780
10.33.5;RESULTS AND DISCUSSION;781
10.33.6;REFERENCES;783
10.34;CHAPTER 170. CHARACTERIZATION OF MONOCLONAL ANTIBODIES TO SUBUNIT A OF CHOLERA TOXIN;784
10.34.1;ABSTRACT;784
10.34.2;KEYWORDS;784
10.34.3;INTRODUCTION;784
10.34.4;METHODS;785
10.34.5;RESULTS AND DISCUSSION;785
10.34.6;ACKNOWLEDGEMENTS;787
10.34.7;REFERENCES;787
10.35;CHAPTER 171. PRODUCTION OF MONOCLONAL ANTIBODIES AGAINST MYCOPLASMA HYORHINIS AS A SECONDARY EFFECT OF IMMUNISATION OF MICE WITH CULTURED CELL LINES;788
10.35.1;ABSTRACT;788
10.35.2;KEY WORDS;788
10.35.3;INTRODUCTION;788
10.35.4;MATERIALS AND METHODS;788
10.35.5;RESULTS AND DISCUSSION;789
10.35.6;ACKNOWLEDGEMENT;791
10.35.7;REFERENCES;791
10.36;CHAPTER 172. MONOCLONAL ANTIBODIES TO THE HUMAN LEUKOCYTE INTERFERONS AND THEIR USE FOR INTERFERON PURIFICATION AND A QUANTITATIVE INTERFERON ASSAY;792
10.36.1;ABSTRACT;792
10.36.2;KEYWORDS;792
10.36.3;INTRODUCTION;792
10.36.4;EXPERIMENTAL PROCEDURES AND RESULTS;792
10.36.5;DISCUSSION;797
10.36.6;REFERENCES;797
10.37;CHAPTER 173. RADIOIMMUNOASSAY (RIA) OF POST-GAMMA GLOBULIN USING A MONOCLONAL ANTIBODY;798
10.37.1;ABSTRACT;798
10.37.2;KEYWORDS;798
10.37.3;INTRODUCTION;798
10.37.4;MATERIALS AND METHODS;798
10.37.5;RESULTS;800
10.37.6;DISCUSSION;800
10.37.7;ACKNOWLEDGMENT;801
10.37.8;REFERENCES;801
10.38;CHAPTER 174. LOCALIZATION OF COLLAGEN TYPE IV IN BASEMENT MEMBRANES BY MONOCLONAL ANTIBODIES;802
10.38.1;ABSTRACT;802
10.38.2;KEYWORDS;802
10.38.3;INTRODUCTION;802
10.38.4;RESULTS;803
10.38.5;DISCUSSION;804
10.38.6;REFERENCES;805
10.39;CHAPTER 175. STUDY OF a1 MICROGLOBULIN (HC PROTEIN) WITH MONOCLONAL ANTIBODIES;806
10.39.1;ABSTRACT;806
10.39.2;KEYWORDS;806
10.39.3;INTRODUCTION;806
10.39.4;MATERIAL AND METHODS;806
10.39.5;RESULTS;807
10.39.6;DISCUSSION;809
10.39.7;ACKNOWLEDGMENT;809
10.39.8;REFERENCES;809
10.40;CHAPTER 176. ANTI-IDIOTYPIC MONOCLONAL ANTIBODIES AGAINST MYASTHENIC ANTIBODIES;810
10.40.1;ABSTRACT;810
10.40.2;KEYWORDS;810
10.40.3;INTRODUCTION;810
10.40.4;METHODS;810
10.40.5;RESULTS AND DISCUSSION;811
10.40.6;ACKNOWLEDGEMENTS;812
10.40.7;REFERENCES;812
10.41;CHAPTER 177. QUANTITATION OF IgGkappa AND IgGlambda IN NORMAL AND PATHOLOGICAL SERA;814
10.41.1;ABSTRACT;814
10.41.2;KEYWORDS;814
10.41.3;INTRODUCTION;814
10.41.4;MATERIALS AND METHODS;815
10.41.5;RESULTS;815
10.41.6;DISCUSSION;815
10.41.7;REFERENCES;817
10.42;CHAPTER 178. USE OF MONOCLONAL ANTIBODIES IN THE CHARACTERISATION OF IMMUNOGLOBULIN CLASSES AND SUBCLASSES IN ANIMAL SPECIES;818
10.42.1;INTRODUCTION;818
10.42.2;MATERIALS AND METHODS;818
10.42.3;REFERENCES;820
10.43;CHAPTER 179. MONOCLONAL ANTIBODIES DIRECTED AGAINST A TORPEDO ELECTRIC ORGAN MEMBRANE ANTIGEN;822
10.43.1;ABSTRACT;822
10.43.2;KEYWORDS;822
10.43.3;INTRODUCTION;822
10.43.4;MATERIALS AND METHODS;822
10.43.5;RESULTS AND DISCUSSION;824
10.43.6;ACKNOWLEDGEMENT;825
10.43.7;REFERENCES;825
10.44;CHAPTER 179. MONOCLONAL ANTIBODIES AGAINST MEMBRANE GLYCOLIPIDS OF AN ANTI-STREPTOCOCCAL GROUP A B-CELL HYBRIDOMA;826
10.44.1;ABSTRACT;826
10.44.2;KEYWORDS;826
10.44.3;INTRODUCTION;826
10.44.4;METHODS AND RESULTS;826
10.44.5;ACKNOWLEDGEMENT;829
10.44.6;REFERENCES;829
10.45;CHAPTER 180. MONOCLONAL ANTIBODY SECRETING MOUSE HYBRIDOMA CLONES EXPRESS DIFFERENT SETS OF MEMBRANE GLYCOSPHINGOLIPIDS IN DIFFERENT ANTIGENIC SYSTEMS;830
10.45.1;ABSTRACT;830
10.45.2;KEY WORDS;830
10.45.3;INTRODUCTION;830
10.45.4;MATERIALS AND METHODS;831
10.45.5;RESULTS AND DISCUSSION;831
10.45.6;REFERENCES;833
10.46;CHAPTER 181. GLYCOSPHINGOLIPID PATTERNS OF ESTABLISHED HUMAN HEMATOPOIETIC CELL LINES;834
10.46.1;ABSTRACT;834
10.46.2;KEY WORDS;834
10.46.3;INTRODUCTION;834
10.46.4;MATERIALS AND METHODS;835
10.46.5;RESULTS AND DISCUSSION;835
10.46.6;REFERENCES;837
10.47;CHAPTER 182. MONOCLONAL ANTIBODIES TO TUMOR-ASSOCIATED GLYCOLIPIDS: PREPARATION AND APPLICATION FOR SUPPRESSION OF TUMOR GROWTH;838
10.47.1;ABSTRACT;838
10.47.2;KEYWORDS;838
10.47.3;INTRODUCTION;838
10.47.4;RESULTS AND DISCUSSION;839
10.47.5;REFERENCES;840
10.48;CHAPTER 183. MONOCLONAL ANTIBODIES AGAINST HUMAN MILKFAT GLOBULE MEMBRANES DETECTING DIFFERENTIATION ANTIGENS OF THE MAMMARY GLAND;842
10.48.1;ABSTRACT;842
10.48.2;KEYWORDS;842
10.48.3;INTRODUCTION;842
10.48.4;MATERIALS AND METHODS;843
10.48.5;RESULTS;844
10.48.6;DISCUSSION;845
10.48.7;ACKNOWLEDGMENTS AND REFERENCES;845
10.49;CHAPTER 184. MONOCLONAL ANTIBODIES IN CLINICAL DIAGNOSIS — REAGENTS FOR DETECTING HORMONES AND IMMUNOGLOBULINS;846
10.49.1;ABSTRACT;846
10.49.2;KEY WORDS;846
10.49.3;ABBREVIATIONS;846
10.49.4;INTRODUCTION;846
10.49.5;RESULTS AND DISCUSSION;847
10.49.6;CONCLUSIONS;849
10.49.7;ACKNOWLEDGEMENT;851
10.49.8;REFERENCES;851
10.50;CHAPTER 186. PRODUCTION OF MONOCLONAL ANTIBODIES TO STEROID HORMONES;852
10.50.1;ABSTRACT;852
10.50.2;KEYWORDS;852
10.50.3;INTRODUCTION;852
10.50.4;MATERIALS AND METHODS;852
10.50.5;RESULTS;853
10.50.6;ACKNOWLEDGEMENTS;855
10.50.7;REFERENCES;855
10.51;CHAPTER 186. MONOCLONAL ANTIBODIES AGAINST GROWTH HORMONE: EFFECTS ON THE HORMONE INTERACTION WITH SPECIFIC CELL SURFACE RECEPTORS;856
10.51.1;ABSTRACT;856
10.51.2;KEYWORDS;856
10.51.3;INTRODUCTION;856
10.51.4;REFERENCES;861
10.52;CHAPTER 187. MONOCLONAL ANTIBODIES AGAINST HUMAN GROWTH HORMONE;862
10.52.1;ABSTRACT;862
10.52.2;KEYWORDS;862
10.52.3;INTRODUCTION;862
10.52.4;MATERIALS AND METHODS;863
10.52.5;RESULTS AND DISCUSSION;864
10.52.6;ACKNOWLEDGEMENT;865
10.52.7;REFERENCES;865
10.53;CHAPTER 188. CHARACTERISTICS OF MONOCLONAL ANTIBODIES AGAINST HUMAN CHORIONIC GONADOTROPHIN;866
10.53.1;ABSTRACT;866
10.53.2;KEYWORDS;866
10.53.3;INTRODUCTION;866
10.53.4;MATERIALS AND METHODS;867
10.53.5;RESULTS AND DISCUSSION;868
10.53.6;ACKNOWLEDGEMENTS;871
10.53.7;REFERENCES;871
10.54;CHAPTER 189. TIVE AND SPECIFIC RIA FOR HUMAN CHORIONIC GONADOTROPIN USING MONOCLONAL ANTIBODIES;872
10.54.1;ABSTRACT;872
10.54.2;INTRODUCTION;872
10.54.3;MATERIAL AND METHODS;872
10.54.4;RESULTS;873
10.54.5;DISCUSSION;875
10.54.6;REFERENCES;875
10.55;CHAPTER 190. THE USE OF MONOCLONAL ANTIBODIES AGAINST PROLACTIN IN A SOLID PHASE ENZYME-IMMUNOASSAY;876
10.55.1;ABSTRACT;876
10.55.2;KEYWORDS;876
10.55.3;INTRODUCTION;876
10.55.4;MATERIALS AND METHODS;876
10.55.5;RESULTS;877
10.55.6;DISCUSSION;879
10.55.7;ACKNOWLEDGEMENT;879
10.55.8;REFERENCES;879
10.56;CHAPTER 191. MOUSE MONOCLONAL ANTIBODIES AGAINST HUMAN PROLACTINE;880
10.56.1;ABSTRACT;880
10.56.2;MATERIALS AND METHODS;880
10.56.3;RESULTS AND DISCUSSION;881
10.56.4;REFERENCES;883
10.57;CHAPTER 192. MONOCLONAL ANTIBODIES TO HUMAN PROLACTIN AND CHORIONIC SOMATOMAMMOTROPIN;884
10.57.1;ABSTRACT;884
10.57.2;KEYWORDS;884
10.57.3;INTRODUCTION;884
10.57.4;GENERATION OF HYBRIDOMA CELL LINES;885
10.57.5;SPECIFICITY OF ANTI-hPRL ANTIBODY QB1;886
10.57.6;SPECIFICITY OF ANTIBODIES TO hCS;887
10.57.7;ANTIBODY-ANTIBODY COMPETITION ASSAY (PACT) OF ANTI-hCS MABs;887
10.57.8;CONCLUSIONS;888
10.57.9;REFERENCES;889
10.58;CHAPTER 193. MONOCLONAL THYROGLOBULIN-AUTOANTIBODIES AS A TOOL TO STUDY AUTOIMMUNITY;890
10.58.1;ABSTRACT;890
10.58.2;KEYWORDS;890
10.58.3;INTRODUCTION;890
10.58.4;MATERIALS AND METHODS;891
10.58.5;RESULTS AND DISCUSSION;891
10.58.6;REFERENCES;893
10.59;CHAPTER 194. MONOCLONAL ANTIBODIES AGAINST TWO ANTIGENS OF CLINICAL INTEREST;894
10.59.1;ABSTRACT;894
10.59.2;KEYWORDS;894
10.59.3;INTRODUCTION;894
10.59.4;RESULTS AND DISCUSSION;895
10.59.5;ACKNOWLEDGEMENTS;897
10.59.6;REFERENCES;897
10.60;CHAPTER 195. MONOCLONAL ANTIBODIES AGAINST HUMAN ACID a-GLUCOSIDASE;898
10.60.1;ABSTRACT;898
10.60.2;KEYWORDS;898
10.60.3;INTRODUCTION;898
10.60.4;MATERIALS AND METHODS;898
10.60.5;RESULTS;899
10.60.6;DISCUSSION;899
10.60.7;ACKNOWLEDGEMENTS;900
10.60.8;REFERENCES;901
10.61;CHAPTER 196. HIGH-AFFINITY MONOCLONAL AUTOANTIBODY USED AS A REAGENT IN A RIA FOR HUMAN CREATINE KINASE BB;902
10.61.1;ABSTRACT;902
10.61.2;KEYWORDS;902
10.61.3;INTRODUCTION;902
10.61.4;MATERIALS AND METHODS;903
10.61.5;RESULTS AND DISCUSSION;903
10.61.6;REFERENCES;905
10.62;CHAPTER 197. FIVE MELANOMA-ASSOCIATED ANTIGENS IDENTIFIED BY MONOCLONAL ANTIBODIES;906
10.62.1;ABSTRACT;906
10.62.2;KEYWORD;906
10.62.3;INTRODUCTION;906
10.62.4;MAJOR FINDINGS;907
10.62.5;DISCUSSION;909
10.62.6;ACKNOWLEDGEMENT;909
10.62.7;REFERENCES;910
10.63;CHAPTER 198. ANTIGEN EXPRESSION AND IMMUNE LYSIS OF HUMAN MELANOMA CELLS: ANALYSIS WITH MONOCLONAL ANTIBODIES;912
10.63.1;ABSTRACT;912
10.63.2;KEYWORDS;912
10.63.3;INTRODUCTION;912
10.63.4;MATERIALS AND METHODS;913
10.63.5;RESULTS AND DISCUSSION;913
10.63.6;ACKNOWLEDGEMENTS;916
10.63.7;REFERENCES;916
10.64;CHAPTER 199. REACTIONS OF MONOCLONAL ANTIBODIES AGAINST HUMAN MELANOMA WITH DIFFERENT TISSUES AND CELL LINES;918
10.64.1;ABSTRACT;918
10.64.2;KEYWORDS;918
10.64.3;INTRODUCTION;918
10.64.4;MATERIAL AND METHODS;919
10.64.5;RESULTS;919
10.64.6;DISCUSSION;920
10.64.7;ACKNOWLEDGEMENT;921
10.64.8;REFERENCES;921
10.65;CHAPTER 200. MOLECULAR HETEROGENEITY OF A HIGH MOLECULAR WEIGHT HUMAN MELANOMA ASSOCIATED ANTIGEN DETECTED BY MONOCLONAL ANTIBODIES;922
10.65.1;ABSTRACT;922
10.65.2;KEYWORDS;922
10.65.3;INTRODUCTION;922
10.65.4;MATERIALS AND METHODS;922
10.65.5;RESULTS AND DISCUSSION;923
10.65.6;ACKNOWLEDGEMENTS;925
10.65.7;REFERENCES;925
10.66;CHAPTER 201. A MONOCLONAL ANTIBODY DEFINING A BURKITT LYMPHOMA ASSOCIATED ANTIGEN;928
10.66.1;ABSTRACT;928
10.66.2;KEYWORDS;928
10.66.3;REFERENCES;931
10.67;CHAPTER 202. PREPARATION AND CHARACTERIZATION OF MONOCLONAL ANTIBODIES AGAINST ANTIGENS OF HUMAN RENAL ADENOCARCINOMA;932
10.67.1;ABSTRACT;932
10.67.2;KEYWORDS;932
10.67.3;INTRODUCTION;932
10.67.4;MATERIALS AND METHODS;934
10.67.5;RESULTS AND DISCUSSION;934
10.67.6;REFERENCES;934
10.68;CHAPTER 203. MONOCLONAL ANTIBODIES AGAINST CARCINOEMBRYONIC ANTIGEN;936
10.68.1;ABSTRACT;936
10.68.2;KEYWORDS;936
10.68.3;INTRODUCTION;936
10.68.4;MATERIAL AND METHODS;936
10.68.5;RESULTS AND DISCUSSION;937
10.68.6;ACKNOWLEDGEMENT;939
10.68.7;REFERENCES;939
10.69;CHAPTER 204. CHARACTERISATION OF MONOCLONAL ANTIBODIES TO CARCINOEMBRYONIC ANTIGEN BY ANTIBODY OVERLAY OF POLYACRYLAMIDE SLAB GELS;940
10.69.1;ABSTRACT;940
10.69.2;KEYWORDS;940
10.69.3;INTRODUCTION;940
10.69.4;MATERIALS AND METHODS;941
10.69.5;RESULTS;941
10.69.6;DISCUSSION;943
10.69.7;REFERENCES;943
10.70;CHAPTER 205. PHASE I TRIALS OF MURINE MONOCLONAL ANTIBODIES TO TUMOR ASSOCIATED ANTIGENS: PRELIMINARY OBSERVATIONS;944
10.70.1;ABSTRACT;944
10.70.2;KEYWORDS;944
10.70.3;INTRODUCTION;944
10.70.4;MATERIALS AND METHODS;944
10.70.5;RESULTS;946
10.70.6;DISCUSSION;948
10.70.7;ACKNOWLEDGEMENT;948
10.70.8;REFERENCES;949
10.71;CHAPTER 206. THE POTENTIAL USE OF MONOCLONAL ANTIBODIES IN DRUG TARGETING;950
10.71.1;ABSTRACT;950
10.71.2;KEYWORDS;950
10.71.3;INTRODUCTION;950
10.71.4;MATERIALS AND METHODS;950
10.71.5;RESULTS;952
10.71.6;DISCUSSION;954
10.71.7;ACKNOWLEDGEMENT;955
10.71.8;REFERENCES;955
10.72;CHAPTER 207. SPECIFIC KILLING OF HUMAN AND MOUSE TUMOR CELLS BY IMMUNOTOXINS;956
10.72.1;ABSTRACT;956
10.72.2;KEYWORDS;956
10.72.3;INTRODUCTION;956
10.72.4;MATERIAL AND METHODS;957
10.72.5;RESULTS AND DISCUSSION;957
10.72.6;CONCLUSIONS;960
10.72.7;ACKNOWLEDGEMENT;960
10.72.8;REFERENCES;961
10.73;CHAPTER 208. DRUG TARGETING WITH MONOCLONAL ANTIBODIES;962
10.73.1;ABSTRACT;962
10.73.2;INTRODUCTION;962
10.73.3;MATERIAL AND METHODS;963
10.73.4;RESULTS;963
10.73.5;CONCLUSION;964
10.73.6;ACKNOWLEGDMENTS;965
10.73.7;REFERENCES;965
10.74;CHAPTER 209. ANALYSIS OF HUMAN HAEMOPOIETIC PRECURSOR CELL ANTIGENS USING ASTATINE LABELLED MONOCLONAL ANTIBODIES;966
10.74.1;ABSTRACT;966
10.74.2;KEY WORDS;966
10.74.3;INTRODUCTION;966
10.74.4;MATERIALS AND METHODS;967
10.74.5;RESULTS AND CONCLUSION;967
10.74.6;ACKNOWLEDGEMENT;969
10.74.7;REFERENCES;969
11;SECTION D: New Methods;970
11.1;CHAPTER 210. THE IGS (IMMUNO GOLD STAINING) METHOD USED WITH MONOCLONAL ANTIBODIES;972
11.1.1;ABSTRACT;972
11.1.2;KEYWORDS;972
11.1.3;INTRODUCTION;972
11.1.4;MATERIAL AND METHODS;973
11.1.5;RESULTS;973
11.1.6;DISCUSSION;975
11.1.7;ACKNOWLEDGEMENT;975
11.1.8;REFERENCES;976
11.2;CHAPTER 211. ENUMERATION OF T LYMPHOCYTES AND THEIR SUBCLASSES IN PERIPHERAL BLOOD BY IMMUNOGOLD STAINING;978
11.2.1;ABSTRACT;978
11.2.2;KEYWORDS;978
11.2.3;INTRODUCTION;978
11.2.4;MATERIALS AND METHODS;979
11.2.5;RESULTS;979
11.2.6;DISCUSSION;981
11.2.7;ACKNOWLEDGMENT;982
11.2.8;REFERENCES;982
11.3;CHAPTER 212. CHROMATOFOCUSING: A NEW HIGH RESOLUTION METHOD FOR PROTEIN FRACTIONATION;984
11.3.1;ABSTRACT;984
11.3.2;KEY WORDS;984
11.3.3;INTRODUCTION;984
11.3.4;DESIGN OF MEDIA FOR CHROMATOFOCUSING;985
11.3.5;EXPERIMENTAL TECHNIQUE FOR CHROMATOFOCUSING;986
11.3.6;RESULTS OBTAINABLE BY CHROMATOFOCUSING;989
11.3.7;ACKNOWLEDGEMENT;989
11.3.8;REFERENCES;989
11.4;CHAPTER 213. THE MULTIWIRE PROPORTIONAL COUNTER FOR THE STUDY OF LIGAND-BINDING OF SERUM PROTEINS;990
11.4.1;ABSTRACT;990
11.4.2;KEYWORDS;990
11.4.3;INTRODUCTION;990
11.4.4;THE BASIC DESIGN OF THE MWPC;991
11.4.5;THE TEST SYSTEM;991
11.4.6;DISCUSSION;993
11.4.7;ACKNOWLEDGEMENT;993
11.4.8;REFERENCES;993
11.5;CHAPTER 214. IDENTIFICATION OF SPECIFIC ANTIGENS OR ANTIBODIES AFTER ELECTROPHORETIC TRANSFER. APPLICATION TO MEASLES VIRUS;994
11.5.1;ABSTRACT;994
11.5.2;KEYWORDS;994
11.5.3;INTRODUCTION;994
11.5.4;MATERIAL AND METHODS;994
11.5.5;ACKNOWLEDGMENT;997
11.5.6;REFERENCES;997
12;AUTHOR INDEX;998
13;SUBJECT INDEX;1006